
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9206/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:44 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9206 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9206 block--content--website-notice-block block--content--website-notice-block--9206 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9206 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9206 block--content--system-main-block block--content--system-main-block--9206 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9206 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-23-000029.rtf%3b%20filename_%3dUTF-8%27%270001157523-23-000029.rtf" type="application/rtf" title="0001157523-23-000029.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-23-000029.pdf%3b%20filename_%3dUTF-8%27%270001157523-23-000029.pdf" type="application/pdf" title="0001157523-23-000029.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-23-000029.xls%3b%20filename_%3dUTF-8%27%270001157523-23-000029.xls" type="application/vnd.ms-excel" title="0001157523-23-000029.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-23-000029.html" type="application/octet-stream" title="0001157523-23-000029-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srrk="http://scholarrock.com/20230109" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_519c1ffdba27485a88e3520e6cbdc84c" contextRef="c20230109to20230109" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_efe5e420d7154287a5b43e5435911680" contextRef="c20230109to20230109">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20230109.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230109to20230109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;">
<div><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">
        </span></div>

        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">
          <br />
        </span></div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED







          STATES<br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
      </div>

      <div style="text-align: center;">
        <hr style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" />
<div><span style="font-weight: bold;"> </span></div>
</div>

      <div style="text-align: center;">
<div><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM







          <ix:nonNumeric name="dei:DocumentType" id="Fact_80dcf76f75ae4c56bcd19a367f0c1e54" contextRef="c20230109to20230109">8-K</ix:nonNumeric></span><br /></div>

        <hr style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_040a93711cb04333a27338c9935553eb" contextRef="c20230109to20230109" format="ixt:datemonthdayyearen">January 9, 2023</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_0729354f3fd149f798083d3253635929" contextRef="c20230109to20230109">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_0119cdb70f6b405cad5ca08526d9d645" contextRef="c20230109to20230109" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a90b5057da994a23abb48f278b2f6d36" contextRef="c20230109to20230109">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b4eff00990c24d3a8bf15d8959ace0eb" contextRef="c20230109to20230109">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e1c9ecf667ec463092237088fa10922f" contextRef="c20230109to20230109">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_dee649e6387249cd94ad06a1cd647c57" contextRef="c20230109to20230109">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_87e377cf4ac7447ba434880405ca83ed" contextRef="c20230109to20230109">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_ce7e2c10d256495b82d6d176f908f34a" contextRef="c20230109to20230109">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_0537e26ad0e94b00adb9c744df3ce90a" contextRef="c20230109to20230109">02142</ix:nonNumeric></span></div>
<div>
        (Address of Principal Executive Offices) (Zip Code)</div>
</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_f920446cf6114df190c68dd28185e70f" contextRef="c20230109to20230109">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_428cb62847bf4a62b1cd679dcedaa877" contextRef="c20230109to20230109">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_f3243db7338f43248b3cf74ae75fe053" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written communications
        pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_9b9d3e65b1e64ec584f933f70da2ce96" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting material
        pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_45a1dc13be7041f895e99ad344f96a82" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement
        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_9e256627453e4b2294bcc55e9e84d2b0" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement
        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_8f74aefae7fd4ed99d90ea60ad826910" contextRef="c20230109to20230109">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_42025c72a4eb4d5fb1f5080766e7100f" contextRef="c20230109to20230109">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_70a7aa59202f4aa4ab79f1ad29f0ed90" contextRef="c20230109to20230109" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_dc70015a0c4a47edbe0b2962f2d72580" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_a219461444734bb69e70422088922aff" contextRef="c20230109to20230109" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

        <div><br />
        </div>

        <div>
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div><br />
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div><br /></div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01. Regulation FD Disclosure.</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 3, 2022, Scholar Rock Holding Corporation (the &#8220;Company&#8221;) announced that management will present at the 41st Annual J.P. Morgan Healthcare
        Conference on Tuesday, January 10, 2023 at 1:30 p.m. PT (4:30 p.m. ET).&#160; A copy of the presentation slide deck that will be presented is being furnished as Exhibit 99.1 to this report on Form 8-K.&#160; A live webcast of the presentation may be accessed
        by visiting the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com.</div>

      <div><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of
        the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section.&#160; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">It may only be incorporated by
          reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K.</span></div>

      <div><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01. Other Events.</div>

      <div><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On January 9, 2023, the Company issued a press release announcing a corporate update and highlighting priorities for 2023.&#160; A copy of this press release is
        being filed herewith as Exhibit 99.2 to this Current Report on Form 8-K.</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</span>&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 92%; vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 92%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53178569ex99_1.htm">99.1</a></div>
            </td>

    <td style="width: 92%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53178569ex99_1.htm">Presentation distributed by Scholar
                  Rock Holding Corporation dated January 9, 2023, furnished hereto</a>.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53178569ex99_2.htm">99.2</a></div>
            </td>

    <td style="width: 92%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53178569ex99_2.htm">Press Release issued by Scholar Rock
                  Holding Corporation dated January 9, 2023</a>.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
            </td>

    <td style="width: 92%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Scholar Rock Holding Corporation</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 48%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 48%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: January 9, 2023</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Junlin Ho</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 48%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Junlin Ho</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 2%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 48%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">General Counsel &amp; Corporate Secretary</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/9206/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:44 GMT -->
</html>
</XBRL>
<div><a name="a53178569ex99_1.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
  </head>
<div bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="z34e71d09ffeb47c4b6eed3440b5d2d8c">

        <tr>
          <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: center;">
      <title></title>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide1.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Deep InsightsAdvancingImpactful Medicines&#160;&#160;January 2023&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide2.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Disclaimers&#160;&#160;Various statements in this presentation concerning the future expectations, plans and
              prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting
              results from its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with
              earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221;
              &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking statements for the purposes of the safe harbor provisions under The Private Securities
              Litigation Reform Act of 1995. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
              adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 trial of apitegromab or
              Part A of the Phase 1 trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including the Phase 3 clinical trial of apitegromab in
              SMA and Part B of the Phase 1 clinical trial of SRK-181, respectively,&#160;Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data
              generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities,&#160;competition from third parties that are developing products for similar uses, Scholar
              Rock&#8217;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#8217;s current and potential future collaborations, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product
              candidates including, without limitation, to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business
              alliances and new business initiatives, and the impacts of current macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, hostilities in Ukraine, increasing rates of inflation and rising interest
              rates, on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, as well as
              discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission.&#160; Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and
              should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by
              law.&#160;&#160;&#160;Apitegromab&#160;and SRK-181 are investigational drug candidates under evaluation.&#160; Apitegromab and SRK-181 have not been approved for any use by the FDA or any other regulatory agency and the safety and efficacy of apitegromab and SRK-181
              have not been established.&#160;&#160;&#169; Scholar Rock, Inc. All rights reserved. &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide3.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Scholar Rock: Transforming Patient Lives, Targeting High Unmet Medical Need&#160;&#160;3&#160;&#160;Global leader in TGFB
              superfamily biology &#160;&#160;Targeting the latent forms of growth factors &#160;&#160;Exquisite selectivity to deliver differentiated therapeutic profiles &#160;&#160;Revolutionary Platform&#160;&#160;Rich preclinical pipeline focused on high unmet patient needs&#160;&#160;&#160;Phase 3
              SAPPHIRE study underway, data readoutexpected in 2024 &#160;&#160;Phase 1 POC DRAGON study underway in immuno-oncology &#160;&#160;Neuromuscular and Beyond&#160;&#160;Compelling proof-of-concept TOPAZ data informed Phase 3 SAPPHIRE study design&#160;&#160;Seasoned leadership team
              with track record of clinical and commercial success &#160;&#160;Anticipated cash runway into 2025&#160;&#160;Positioned&#160;&#160;for Success&#160;&#160;Commercial planning underway for apitegromab (SMA) in US and Europe&#160;&#160;&#160;Broad platform, including promising early-stage assets,
              provides opportunities to advance alone or in partnership&#160;&#160;Strategic Optionality &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide4.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Revolutionary Approach to Regulating TGF&#946; Superfamily Implicated in Devastating Diseases&#160;&#160;4&#160;&#160;Scholar
              Rock&#8217;s R&amp;D Platform&#160;&#160;Transforming Medical Practice&#160;&#160;Selectively target the latent form of growth factors in the microenvironment of cells and tissues with uniquely designed antibodies&#160;&#160;Overcome the challenges that plague traditional
              approaches that target the &#8220;mature&#8221; growth factor, which are difficult to differentiate and lead to unintended negative effects&#160;&#160;Scholar Rock&#8217;s TargetLatent Growth Factor&#160;&#160;Traditional Target&#8220;mature&#8221; growth factor&#160;&#160;TGF&#946; Superfamily: Highly
              Sought-After Targets &#160;&#160;Dysregulation plays a role in devastating diseases that have a high unmet need including:&#160;&#160;Neuromuscular disorders &#160;&#160;&#160;Fibrosis&#160;&#160;Oncology&#160;&#160;Recognized by the industry as important targets given their fundamental roles in
              regulating a variety of cellular processes&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide5.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DISCOVERY/PRECLINICAL&#160;&#160;PHASE 1&#160;&#160;PHASE 2&#160;&#160;PHASE 3&#160;&#160;2023 MILESTONES&#160;&#160;SPINAL MUSCULAR ATROPHYApitegromab
              (selective anti-latent myostatin)&#160;&#160;36-month TOPAZ data&#160;&#160;SAPPHIRE: LPI &#160;&#160;&#160;IMMUNO-ONCOLOGYSRK-181 (Selective context-independent, anti-latent TGF&#946;-1)&#160;&#160;Rolling clinical data updates&#160;&#160;ANEMIASelective anti-RGMc&#160;&#160;IND-enabling
              studies&#160;&#160;FIBROSIS&#160;&#160;Selective context-dependent (LTBP1 &amp; LTBP3) anti-latent TGF&#946;-1&#160;&#160;&#160;IND-enabling studies&#160;&#160;Robust Pipeline of Novel Product Candidates &#160;&#160;5&#160;&#160;Potential to transform the lives of patients suffering from a wide range of serious
              diseases, including neuromuscular disorders, oncology, and fibrosis&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide6.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Leadership Team: Experienced in Drug Development and Commercialization&#160;&#160;6&#160;&#160;Jay Backstrom, MD,
              MPH&#160;&#160;President &amp; CEO&#160;&#160;30 years of clinical R&amp;D experience, leading multiple successful regulatory approvals&#160;&#160;Ted Myles, MBA&#160;&#160;Chief Operating Officer &amp; CFO&#160;&#160;25 years of progressive experience in clinical and commercial-stage
              companies &#160;&#160;25 years of experience leading HR, culture transformation, leadership development, DEI, and talent management&#160;&#160;Caryn Parlavecchio&#160;&#160;Chief Human Resources Officer&#160;&#160;15 years of experience leading and advising life sciences companies
              in areas of legal and compliance &#160;&#160;Junlin Ho, JD&#160;&#160;General Counsel &amp;Corporate Secretary&#160;&#160;Mo Qatanani, PhD&#160;&#160;SVP, Research&#160;&#160;15 years of industry experience on the strategic and operational sides of research &amp; development&#160;&#160;Jing Marantz,
              MD, PhD, MBA&#160;&#160;Chief Medical Officer &#160;&#160;20 years of industry expertise across clinical pharmacology, neurology, hematology/oncology, and rare diseases&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide7.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab: The Next Potential Transformative Therapy for Patients with Spinal Muscular Atrophy (SMA)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide8.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab: Potential Muscle-Directed Therapy for SMA&#160;&#160;8&#160;&#160;*&#160;Based on Animal Model Data; 1. Adapted
              from: SMA Foundation Overview. http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.;&#160;Accessed April 18, 2021; 2. Long KK, et al. Hum Mol Genet. 2019;28(7):1077-1088; 3. Pirruccello-Straub M, et al. Sci Reports.
              2018;8(1):2292. doi:10.1038/s41598-018-20524-9&#160;&#160;Apitegromab is a&#160;&#160;MUSCLE-DIRECTED APPROACH&#160;&#160;aimed at improving motor function*2,3&#160;&#160;Myostatin is a negative regulator of skeletal muscle growth&#160;&#160;Apitegromab is a fully human, mAb that
              specifically binds to proforms of myostatin and inhibits myostatin activation leading to increased muscle mass and muscle function &#160;&#160;Strong evidence indicates upstream targeting of structurally differentiated latent myostatin avoids
              undesirable off-target effects &#160;&#160;Apitegromab&#160;&#160;Muscle fiber atrophy&#160;&#160;SMN-directed therapiesPREVENT FURTHER DEGENERATION of motor neurons1&#160;&#160;...but do not directly address muscle atrophy&#160;&#160;Motor neuron&#160;&#160;degeneration&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide9.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;9&#160;&#160;*TOPAZ Phase 2 trial evaluated patients with Type 2 and 3 SMA (did not include Type 1)&#160;&#160;1. Lally et
              al, Orphanet Journal of Rare Diseases, 2017; 2. SMA Europe. SMATracker. About SMA. Accessed January 24, 2022. https://smatracker.eu/what-is-spinal-muscular-atrophy; 3. National Organization for Rare Disorders. Spinal muscular atrophy.
              Accessed January 24, 2022. https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. 4. Cure SMA. Care Series Booklet. Accessed September 19, 2021. 2020.
              https://www.curesma.org/wpcontent/uploads/2020/08/08262020_Understanding_SMA_vWeb.pdf. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any
              use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Severe, progressive disabilities and unable to walk independently&#160;&#160;Significant, progressive motor function impairment; many lose
              ambulation&#160;&#160;Infantile onset; unable to sit up independently&#160;&#160;Type 3&#160;&#160;35%&#160;&#160;Type 2&#160;&#160;51%&#160;&#160;Type 1&#160;&#160;14%&#160;&#160;TOPAZ* 12-month results showed transformative potential in non-ambulatory Types 2 and 3 patients&#160;&#160;&gt;2/3 of overall &#160;&#160;patient population&#160;&#160;KBV
              Research and secondary Research Analysis. Global Spinal Muscular Atrophy Market Analysis (2022-2028). November 2022, p. 42&#160;&#160;Global SMA Treatment Market expected to reach $11.4B by 2028&#160;&#160;Spinal Muscular Atrophy&#160;&#160;Motor neuron impairment and
              loss due to SMN genetic deficiency, leading to muscle atrophy and weakness&#160;&#160;GLOBAL DISEASE:&#160;&#160;30,000-35,000 affected in US and Europe alone1, 2, 3,4&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide10.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Patients continue to experience major functional impairments despite utilization of SMN-directed
              therapies&#160;&#160;Potential to Pioneer a New Treatment Era: Opportunity for Muscle-Directed Therapy to Complement SMN-Directed Therapies&#160;&#160;10&#160;&#160;PHASE 3 TRIAL DESIGN&#160;&#160;Type 1, 2 ,3 &#160;&#160;1 day -12 years of age&#160;&#160;(Non-ambulatory recruited)&#160;&#160;Type 1, 2, 3&#160;&#160;1
              month &#8211; 25 years of age&#160;&#160;(Ambulatory and Non-ambulatory recruited)&#160;&#160;Type 1&#160;&#160; up to 6 months of age&#160;&#160;(Non-ambulatory recruited)&#160;&#160;PRIMARY ENDPOINT&#160;&#160;Mean change from baseline&#160;&#160;in HFMSE at 15 months&#160;&#160;Mean change from baseline&#160;&#160;in MFM-32 at 12
              months&#160;&#160;Ability to sit independently&#160;&#160;and event-free survival&#160;&#160;INITIAL INDICATION&#8224;&#160;&#160;Spinal Muscular Atrophy (SMA) in pediatric and adult patients&#160;&#160;Spinal Muscular Atrophy (SMA) in pediatric and adult patients&#160;&#160;Spinal Muscular Atrophy (SMA) in
              pediatric patients less than 2 years&#160;&#160;CURRENT MARKET PENETRATION&#160;&#160;Patients treated WW: &gt;11,000* &#160;&#160;Revenues (LTM): $1.7+ billion &#160;&#160;Patients treated WW: &gt;7000** &#160;&#160;Revenues (YTD&#8217;0922): ~CHF 793 million&#160;&#160;Patients treated WW: &gt;2500***
              &#160;&#160;Revenues (LTM): $ 1.4+ billion &#160;&#160;*As of Biogen SPINRAZA website and 3Q22 financial update on 10/25/22; includes patients treated worldwide in post-marketing setting, expanded access program, and clinical trials. **As of Roche YTD Sep&#8217;2022
              financial update on 10/18/22; includes patients treated worldwide between clinical trials, commercial, and compassionate use program.&#160;&#160;***As of Novartis 3Q22 financial update on 10/25/22; commercially, via managed access programs and in
              clinical trials&#160;&#160;HFMSE = Hammersmith Functional Motor Scale Expanded; MFM-32 = Motor Function Measure &#8211; 32 items &#160;&#160;&#8224;Refer to most current USPI&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide11.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab Offers Potential to Address Unmet Patient Need&#160;&#160;11&#160;&#160;HFMSE=Hammersmith Functional Motor
              Scale-Expanded &#160;&#160;1. Mercuri E et al.;&#160;N Engl J Med 2018; 378:625-635; DOI: 10.1056/NEJMoa1710504; cherish trial results. This third-party information is provided for background only and is not intended to convey or imply a comparison to the
              TOPAZ clinical trial results.&#160;&#160;Mean improvement in HFMSE experienced by patients with&#160;&#160;non-ambulatory Types 2/3 SMA in nusinersen Phase 3 CHERISH trial&#160;&#160;3.9-point increase in HFMSE from nusinersen(4.9 point increase relative to sham
              control)&#160;&#160;HFMSE Score at Month 15&#160;&#160;Total Possible HFMSE Score of 66&#160;&#160;Unmet need remains substantial &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide12.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Phase 2 TOPAZ Trial: Safety and Efficacy Data from First Muscle-directed Treatment Candidate in SMA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide13.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Age 2-12 Analysis* in Pooled Non-Ambulatory Cohorts (20mg/kg) Transformative Potential as Add-On
              for Apitegromab1,2&#160;&#160;13&#160;&#160;Mean HFMSE Increase&#160;&#160;OF 4.4 POINTS&#160;&#160;with majority experiencing &#8805; 3-point increases on top of background SMN therapy&#160;&#160;HFMSE Gains Also Notable&#160;&#160;in subset of individuals in this analysis who had started background
              nusinersen at age &#8805; 5: &#160;&#160;75% (6/8) with &#8805; 1-point increase&#160;&#160;50% (4/8) with &#8805; 3-point increase&#160;&#160;Non-Ambulatory Types 2/3 SMA&#160;&#160;(Apitegromab 20 mg/kg; Intent-to-Treat Population)&#160;&#160;Age 2-12 years&#160;&#160;(n=16&#8224;)&#160;&#160;Mean HFMSE change from baseline, (95%
              CI)&#160;&#160;+4.4 (1.3, 7.4)&#160;&#160;Patients with &#8805; 1-pt increase in HFMSE, n (%)&#160;&#160;13 (81%)&#160;&#160;Patients with &#8805; 3-pt increase in HFMSE, n (%)&#160;&#160;9 (56%)&#160;&#160;TOPAZ results showed HFMSE improvement from baseline or RHS stabilization across all three pre-specified
              cohorts.1&#160;&#160;*Exploratory, post hoc analysis; &#8224;For 12-month endpoint, if patients skipped three consecutive doses due to site restrictions caused by COVID-19, records after dose skipping were excluded from analysis. The last observation carry
              forward was used for other missing data; 1.Crawford T et al. TOPAZ topline results; Presented at CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021. 2. Scholar Rock Inc. Corporate Presentations, August 2022 at
              Deep Insights, Impactful Medicines (scholarrock.com)&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other
              health authority, and its safety and efficacy have not been established.&#160;&#160;No safety signals for apitegromab were identified to date; the five most frequently reported treatment-emergent adverse events were headache, pyrexia, upper respiratory
              tract infection, cough, and nasopharyngitis&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide14.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Sizable, Sustained Increases in HFMSE Observed Over 24 Months of ApitegromabPooled Non-Ambulatory
              Patients Excluding Data Post Scoliosis Surgery (all dose groups)&#160;&#160;14&#160;&#160;For the 24-month evaluation, an observed case analysis was conducted, which pooled all the non-ambulatory patients (Cohorts 2 and 3) and was based upon the available data
              for given timepoints. This analysis population included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). This analysis
              excludes from the observed case analysis any HFMSE data following scoliosis surgery in TOPAZ. Of the three non-ambulatory patients who had scoliosis surgery, data from one was excluded and the other two did not have valid HFMSE assessments.
              Error bars represent SEM. Values in parentheticals represent 95% confidence interval. Crawford T et al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TYPE 2 AND TYPE 3 SMA)
              Podium Presentation Presented at CureSMA; June 2022. Data on File. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been
              approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Age 2-21 Years&#160;&#160;Age 2-12 Years&#160;&#160;n=&#160;&#160;35&#160;&#160;29&#160;&#160;32&#160;&#160;28&#160;&#160;n=&#160;&#160;29&#160;&#160;23&#160;&#160;26&#160;&#160;23&#160;&#160;Mean Change from Baseline in HFMSE (95% CI) &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide15.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Continued Increase in RULM Observed at 24 Months of Apitegromab Pooled Non-Ambulatory Patients
              Excluding Data Post Scoliosis Surgery (all dose groups)&#160;&#160;15&#160;&#160;For the 24-month evaluation, an observed case analysis was conducted, which pooled all the non-ambulatory patients (Cohorts 2 and 3) and was based upon the available data for given
              timepoints. This analysis population included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). This analysis excludes data
              from 3 non-ambulatory patients after their scoliosis surgery during TOPAZ from the Observed Case Analysis. Error bars represent SEM. Values in parentheticals represent 95% confidence interval. Crawford T et al. TOPAZ EXTENSION: 24-MONTH
              EFFICACY AND SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TYPE 2 AND TYPE 3 SMA) Podium Presentation Presented at CureSMA; June 2022. Data on File. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an
              investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been
              established.&#160;&#160;n=&#160;&#160;34&#160;&#160;28&#160;&#160;31&#160;&#160;30&#160;&#160;n=&#160;&#160;28&#160;&#160;22&#160;&#160;25&#160;&#160;25&#160;&#160;Mean Change from Baseline in RULM (95% CI) &#160;&#160;Age 2-21 Years&#160;&#160;Age 2-12 Years&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide16.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;No Serious Safety Risks IdentifiedOver 24 Months of Apitegromab Treatment &#160;&#160;16&#160;&#160;Treatment-Emergent
              Adverse Events (TEAEs)*&#160;&#160;2 mg/kg dose &#160;&#160;(N=10)&#160;&#160;n (%)&#160;&#160;20 mg/kg dose &#160;&#160;(N=48)&#160;&#160;n (%)&#160;&#160;Total&#160;&#160;(N=58)&#160;&#160;n (%)&#160;&#160;Any TEAE&#160;&#160;10 (100)&#160;&#160;45 (93.8)&#160;&#160;55 (94.8)&#160;&#160;Any Serious TEAE&#160;&#160;3 (30)&#160;&#160;11 (22.9)&#160;&#160;14 (24.1)&#160;&#160;Any TEAE leading to study drug
              discontinuation&#160;&#160;0 (0.0)&#160;&#160;1 (2.1)&#160;&#160;1 (1.7)&#160;&#160;Any Grade 3 (severe) or higher TEAE&#160;&#160;2 (20)&#160;&#160;9 (18.8)&#160;&#160;11 (19)&#160;&#160;Crawford T et al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
              (TYPE 2 AND TYPE 3 SMA) Podium Presentation Presented at CureSMA; June 2022&#160;&#160;*Notes: % = 100 x n/N (n=incidence)&#160;&#160;**51/57 patients &#160;&#160;Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) that start after the first dose
              of study drug or start prior to the administration of study drug and worsen in severity/grade or relationship to investigational medication after the administration of study drug. Data is for safety events collected over the 24-month period
              and includes patients who switched from 2 mg/kg to 20 mg/kg. Data on file, extracted on April 7, 2022. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular
              atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Incidence and types of TEAEs were consistent with the underlying disease or nusinersen
              therapy&#160;&#160;Five most frequently reported TEAEs were headache, pyrexia, upper respiratory tract infection, cough, and nasopharyngitis&#160;&#160;No deaths or Suspected Unexpected Serious Adverse Reactions (SUSARs) reported&#160;&#160;Adverse events reported as
              mostly mild to moderate in severity&#160;&#160;No identified serious risks as of 4/7/2022&#160;&#160; approximately 90% remain on apitegromab as of 12/31/2022**&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide17.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Sapphire Phase 3 Pivotal Trial&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide18.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Ongoing SAPPHIRE Phase 3 Trial Overview&#160;&#160;18&#160;&#160;Randomized, double-blind, placebo-controlled, parallel arm
              design (n=204)&#160;&#160;Enrolling patients on SMN-directed therapy (nusinersen or risdiplam)&#160;&#160;Anticipate completing enrollment in 2023&#160;&#160;TREATMENT (52 weeks)&#160;&#160;Apitegromab (20 mg/kg IV q4w) + SMN-directed therapy&#160;&#160;Apitegromab (10 mg/kg IV q4w) +
              SMN-directed therapy&#160;&#160;Placebo (IV q4w) + SMN-directed therapy&#160;&#160;SCREENING&#160;&#160;MAIN POPULATION (n=156)&#160;&#160;Ages 2-12&#160;&#160;With non-ambulatory Types 2 and 3 SMA&#160;&#160;N=52&#160;&#160;N=52&#160;&#160;N=52&#160;&#160;R&#160;&#160;Stratified randomization to ensure balanced allocation: &#160;&#160;Age at SMN
              therapy initiation(age &lt; 5 vs age &#8805; 5) &#160;&#160;SMN therapy (nusinersen vs. risdiplam)&#160;&#160;ENDPOINTS&#160;&#160;Primary Efficacy:&#160;&#160;Mean HFMSE change from baseline at 12 months &#160;&#160;Additional Efficacy Measures:&#160;&#160;RULM, WHO, other outcome measures &#160;&#160;Safety, PK/PD,
              ADA&#160;&#160;Additional Data Opportunities&#160;&#160;Exploratory population (age 13-21), in patients using SMN therapy&#160;&#160;Focused upon safety &amp; exploratory efficacy (n=48; 2:1 randomization between apitegromab 20 mg/kg vs placebo)&#160;&#160;Separate open-label
              extension study (after patients complete 12-month treatment period)&#160;&#160;Focused upon safety &amp; exploratory long-term efficacy&#160;&#160;ClinicalTrials.gov Identifier: NCT05156320&#160;&#160;R=Randomization &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide19.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;2023 enrollment&#160;&#160;2024 data&#160;&#160;2025 launch &#160;&#160;Executing on the Promise: Apitegromab SMA Trials&#160;&#160;19&#160;&#160;WHERE
              WE WERE Phase 2&#160;&#160;12-Month&#160;&#160;COMPLETE&#160;&#160;24-Month&#160;&#160;EXTENSION&#160;&#160;COMPLETE&#160;&#160;WHERE WE AREPhase 3&#160;&#160;WHERE WE PLAN TO GO&#160;&#160;36-Month&#160;&#160;EXTENSION&#160;&#160;IN PROCESS&#160;&#160;12-Month&#160;&#160;IN PROCESS&#160;&#160;Ambulatory patients&#160;&#160;Type 1 patients (including those treated with gene
              therapy, under 2 years of age)&#160;&#160;Long-term&#160;&#160;EXTENSION&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide20.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Potential Transformative Backbone for a New Era ofCancer Immunotherapy&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide21.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Resistance to Checkpoint Inhibitor (CPI) Therapies Remains a Significant Clinical Challenge&#160;&#160;21&#160;&#160;1.
              Source: Gores, M. (2022).&#160;In the eye of the storm: PD-(L)1 inhibitors weathering turbulence [White paper]. &#160;IQVIA.&#160;https://www.iqvia.com/library/white-papers/in-the-eye-of-the-storm-pd-l-1-inhibitors-weathering-turbulence &#160;&#160;2. Source:
              Carretero-Gonzalez et al. (2018) Oncotarget 9:8706-8715&#160;&#160;Meta-analysis of twelve randomized trials with control arm or adequate safety profile (includes nivolumab, pembrolizumab, and atezolizumab)&#160;&#160;Clinically derived rationale points to
              significant opportunity to increase checkpoint therapy responses by targeting TGF&#946;-1 &#160;&#160;7.9-10.41MILLION US patients on CPI therapies&#160;&#160;First-lineCPI therapy&#160;&#160;Second-line(or later) CPI therapy&#160;&#160;DID NOT respond &#160;&#160;63%&#160;&#160;2&#160;&#160;78%&#160;&#160;2&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide22.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Strong Scientific Rationale for the Role of TGF&#946; Inhibition in Immuno-Oncology&#160;&#160;22&#160;&#160;&#8220;Bristol Myers
              Squibb Enters Agreement to Acquire Forbius TGF-beta Program&#8221;&#160;&#160;August 2022.&#160;&#160;&#8220;Merck to Acquire Tilos Therapeutics: Merck Gains Portfolio of Investigational Antibodies Modulating TGF&#946;&#8221;&#160;&#160;$773 million total potential deal value&#160;&#160;June
              2019.&#160;&#160;Selective inhibition of TGF&#946;-1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape&#160;&#160;Science Translational Medicine, March 25, 2020.&#160;&#160;Constance J. Martin, et al.&#160;&#160;Vol 12, Issue 536.
              DOI: 10.1126/scitranslmed.aay8456&#160;&#160;Nature (online), February 14, 2018.&#160;&#160;TGF&#946; attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells&#160;&#160;Sanjeev Mariathasan1*, Shannon J. Turley1*, Dorothee Nickles1*, Alessandra
              Castiglioni1, Kobe Yuen1, Yulei Wang1,&#160;&#160;Edward E. Kadel III1, Hartmut Koeppen1, Jillian L. Astarita1, Rafael Cubas1, Suchit Jhunjhunwala1, Romain Banchereau1,&#160;&#160;Yagai Yang1, Yinghui Guan1, Cecile Chalouni1, James Ziai1, Yasin &#350;enbabao&#287;lu1,
              Stephen Santoro1, Daniel Sheinson1, &#160;&#160;Jeffrey Hung1, Jennifer M. Giltnane1, Andrew A. Pierce1, Kathryn Mesh1, Steve Lianoglou1, Johannes Riegler1,&#160;&#160;Richard A. D. Carano1, Pontus Eriksson2, Mattias H&#246;glund2, Loan Somarriba3, Daniel L.
              Halligan3, Michiel S. van der Heijden4,&#160;&#160;Yohann Loriot5, Jonathan E. Rosenberg6, Lawrence Fong7, Ira Mellman1, Daniel S. Chen1, Marjorie Green1, Christina Derleth1,&#160;&#160;Gregg D. Fine1, Priti S. Hegde1, Richard Bourgon1 &amp; Thomas
              Powles8&#160;&#160;Willy Hugo, Jesse M. Zaretsky, Lu Sun, Douglas B. Johnson, Antoni Ribas, Roger S. Lo&#160;&#160;Volume 165, Issue 1,&#160;24 March 2016, Pages 35-44&#160;&#160;Genomic and Transcriptomic Features of Response&#160;&#160;to Anti-PD-1 Therapy in Metastatic Melanoma&#160;&#160;July
              24, 2020: https://doi.org/10.1038/ s41571-020-0403-1&#160;&#160;Nature Reviews , July 24, 2020&#160;&#160;NATURE REVIEWS | CLINICAL ONCOLOGY&#160;&#160;TGF&#946;: biology in cancer progression&#160;&#160;and immunotherapy&#160;&#160;Rik Derynck1,2,3, Shannon J. Turley4 and Rosemary J.
              Akhurst2,3&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide23.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Unique Latent TGF&#946;-1&#160;Selective Approach to Overcoming Checkpoint Inhibitor
              Resistance&#160;&#160;23&#160;&#160;Traditional Target&#8220;Mature&#8221; growth factor&#160;&#160;1. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than
              active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 1990 Dec;86(6):1976-84. doi: 10.1172/JCI114932. PMID: 2254455; PMCID: PMC329834.&#160;&#160;SRK-181: Latent TGF&#946;-1 Inhibitor&#160;&#160;Targets TGF&#946;-1&#160;&#160;Potential to
              overcome CPI resistance&#160;&#160;SRK-181 inhibits the TGF&#946;-1 implicated in check point inhibitor resistance&#160;&#160;Selective to &#946;-1 isoform&#160;&#160;Highly selective to &#946;-1 isoform vs. 2 and 3&#160;&#160;Increases therapeutic window and potentially avoids toxicities
              associated with non-selective TGF&#946; inhibition&#160;&#160;Other programs target multiple isoforms of TGF&#946;&#160;&#160;Context-independent&#160;&#160;Inhibits all sources of TGF&#946;-1&#160;&#160;SRK-181 targets all TGF&#946;-1 sources (LRRC33, GARP and LTBP1 and 3)&#160;&#160;Some programs only target
              one source&#160;&#160;Targets the latent form of TGF&#946;-1 &#160;&#160;Selectively targeting the latent form shuts off the growth factor before activation &#160;&#160;Increases opportunity to inhibit TGF&#946;-1&#160;&#160;Most other programs target the mature form of TGF&#946;-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide24.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181-mIgG1 + Anti-PD1 Overcomes Immune Exclusion&#160;&#160;24&#160;&#160;Anti-PD1/ SRK-181-mIgG1&#160;&#160;Anti-PD1&#160;&#160;Overcoming
              immune exclusion&#160;&#160;Tumor micro-environment&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med. 2020 Mar 25;12(536):eaay8456. https://scholarrock.com/platform/publications.&#160;&#160;Data from MBT-2 syngeneic
              tumor model. Dose 10mg/kg QW for 4 weeks. &#160;&#160;Overcome Exclusion&#160;&#160;SRK-181-mIgG1 combination therapy led to influx and amplication of cytotoxic CD8+ cells in preclinical bladder tumor model&#160;&#160;Immune Exclusion&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide25.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DRAGON Phase 1 POC Trial to Evaluate SRK-181&#8217;s Ability to Overcome Primary Resistance to Checkpoint
              Inhibitors&#160;&#160;25&#160;&#160;* A cohort of 2000 mg Q2W (n=3) was also evaluated.&#160;&#160;**The clear cell RCC cohort will also explore the effects of SRK-181 in patients with relapsed response after anti-PD-(L)1 treatment.&#160;&#160;1. NCT04291079 on
              www.clinicaltrials.gov.&#160;&#160;PART B&#160;&#160;SRK-181 + anti-PD-(L)1;&#160;&#160;non-responders to prior anti-PD-(L)1&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Non-small cell lung cancer&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Urothelial carcinoma&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Cutaneous
              melanoma&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Clear cell renal cell carcinoma** &#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Head and neck small cell carcinoma&#160;&#160;COHORT&#160;&#160;TREATMENT&#160;&#160;PART A&#160;&#160;SRK-181 80 mg (n=1)&#160;&#160;SRK-181 240 mg (n=1)&#160;&#160;SRK-181 800 mg (n=3)&#160;&#160;SRK-181 1600 mg
              (n=3)&#160;&#160;SRK-181 2400 mg (n=3)&#160;&#160;SRK-181 3000 mg (n=3)*&#160;&#160;SRK-181 &#160;&#160;all-comers&#160;&#160;A1&#160;&#160;A2&#160;&#160;SRK-181+anti-PD-(L)1; non-responders to prior anti-PD-(L)1&#160;&#160;SRK-181 240 mg (n=3)&#160;&#160;SRK-181 800 mg (n=3)&#160;&#160;SRK-181 1600 mg (n=3)&#160;&#160;SRK-181 2400 mg (n=3)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide26.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;DRAGON Part A: Safety &#160;&#160;26&#160;&#160;PART A1&#160;&#160;Treatment-Emergent AEs Related to SRK-181, All Grades &gt;10%
              &#160;&#160;PART A2&#160;&#160;Treatment-Emergent AEs Related to SRK-181 or Anti-PD(L)1, All Grades &gt;10%&#160;&#160;Dose (MG)&#160;&#160;80N=1&#160;&#160;240N=1&#160;&#160;800N=3&#160;&#160;1600N=4&#160;&#160;2400N=3&#160;&#160;3000N=3&#160;&#160;2000N=4&#160;&#160;AllN=19&#160;&#160;Fatigue&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;3 (15.8%)&#160;&#160;Decreased
              Appetite&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;2 (10.5%)&#160;&#160;Nausea&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;1&#160;&#160;2 (10.5%)&#160;&#160;Dose (MG)&#160;&#160;240N=3&#160;&#160;800N=3&#160;&#160;1600N=6&#160;&#160;2400N=3&#160;&#160;AllN=19&#160;&#160;Pruritis&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;1&#160;&#160;3 (20.0%)&#160;&#160;Rash&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;2&#160;&#160;3 (20.0%)&#160;&#160;Rash maculo-papular&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;1&#160;&#160;3
              (20.0%)&#160;&#160;Diarrhea&#160;&#160;0&#160;&#160;0&#160;&#160;2&#160;&#160;0&#160;&#160;2 (13.3%)&#160;&#160;Yap T et al. SRK-181, a latent TGF&#946;1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors
              (Poster 780); Presented at SITC; Nov. 10-11, 2022. Clinical cutoff date: August 29, 2022. All dose levels were administered q3w except 2000 mg, which was administered q2w.&#160;&#160;SRK-181 is an investigational drug candidate that is being evaluated
              for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety and efficacy have not been established. &#160;&#160;Treatment-related Grade 3 AEs:&#160;&#160;Alanine aminotransferase increased (1
              patient)&#160;&#160;Treatment-related SAE were elevated troponin I (1 patient, at 2000 mg q2w)&#160;&#160;No DLTs&#160;&#160;were observed up to 3000 mg q3w and 2000 mg q2w&#160;&#160;No Grade 4 or 5 treatment-related AEs occurred&#160;&#160;Treatment-related Grade 3 AEs:&#160;&#160;Puritus (2
              patients), blister, immune-mediated lung disease, rash and rash maculo-popular(1 patient each)&#160;&#160;Treatment-related SAEs:&#160;&#160;Blister, pruritus, and rash (all in 1 patient) and immune-mediated lung disease (1 patient)&#160;&#160;No DLTs&#160;&#160;were observed up to
              2400 mg q3w&#160;&#160;No Grade 4 or 5 treatment-related AEs occurred&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide27.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;Ovarian&#160;&#160;Ovarian&#160;&#160;Ovarian&#160;&#160;Pancreatic&#160;&#160;Pancreatic&#160;&#160;Colorectal&#160;&#160;Colorectal&#160;&#160;Colorectal&#160;&#160;Colorectal&#160;&#160;Colorectal&#160;&#160;Colorectal&#160;&#160;Testicular&#160;&#160;Prostate&#160;&#160;Prostate&#160;&#160;Prostate&#160;&#160;Prostate&#160;&#160;Primary
              Unknown&#160;&#160;Primary Unknown&#160;&#160;Head and Neck&#160;&#160;Months&#160;&#160;0&#160;&#160;1&#160;&#160;2&#160;&#160;3&#160;&#160;4&#160;&#160;5&#160;&#160;6&#160;&#160;7&#160;&#160;8&#160;&#160;9&#160;&#160;10&#160;&#160;11&#160;&#160;12&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;Head and Neck&#160;&#160;Head and Neck&#160;&#160;RCC&#160;&#160;Melanoma&#160;&#160;Squamous Cell Skin Carcinoma&#160;&#160;RCC&#160;&#160;Melanoma&#160;&#160;TNCB&#160;&#160;Head and
              Neck&#160;&#160;Liver&#160;&#160;NSCLC&#160;&#160;RCC&#160;&#160;RCC&#160;&#160;Uveal Melanoma&#160;&#160;Primary Unknown&#160;&#160;Progressed on Prior&#160;&#160;Anti-PD-(L)1&#160;&#160;Duration of Treatment&#160;&#160;DRAGON Part A: Preliminary Efficacy Data* Presented at SITC November 2022&#160;&#160;27&#160;&#160;Part A1 (n=19)&#160;&#160;Part A2 (n=15)&#160;&#160;8 patients
              had a best response of stable disease (SD) &#160;&#160;All 3 patients with ovarian cancer were stable beyond the 16-week cutoff &#160;&#160;Yap T et al. SRK-181, a latent TGF&#946;1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion
              of a phase I trial (DRAGON trial) in patients with advanced solid tumors (Poster 780); Presented at SITC; Nov. 10-11, 2022. *Preliminary anti-tumor effects were assessed using RECIST1.1 and reported based upon local investigator reads: as of
              August 29, 2022. &#160;&#160;SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety and efficacy have not been
              established.&#160;&#160;At 800 mg q3w, 1 partial response (PR) was observed in patient with anti-PD-1-resistant clear cell renal cell carcinoma (ccRCC)&#160;&#160;9 patients had best response of SD&#160;&#160;6 patients (green highlight) were stable beyond the 16-week
              cutoff &#160;&#160;1 ongoing patient with head and neck cancer had a 29.4% tumor reduction &#160;&#160;Clinical cutoff date: 29AUG2022&#160;&#160;Best Response of PR&#160;&#160;Best Response of SD&#160;&#160;Best Response of PD&#160;&#160;Not Evaluated&#160;&#160;Partial Response&#160;&#160;Progressive
              Disease&#160;&#160;Ongoing&#160;&#160;Discontinued&#160;&#160;X&#160;&#160;Assessments:&#160;&#160;2400 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;240 mg q3w&#160;&#160;2000 mg q2w&#160;&#160;2000 mg q2w&#160;&#160;2400 mg q3w&#160;&#160;2000 mg q2w&#160;&#160;800 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;3000 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;3000 mg q3w&#160;&#160;80 mg q3w&#160;&#160;1600 mg
              q3w&#160;&#160;800 mg q3w&#160;&#160;3000 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;2000 mg q2w&#160;&#160;240 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;800 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;800 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;800 mg q3w&#160;&#160;240 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;240 mg q3w&#160;&#160;1600 mg
              q3w&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide28.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Preliminary Efficacy Data in Combination with Pembrolizumab: Best Response in Target Lesions&#160;&#160;28&#160;&#160;Best
              Response in Target Lesions&#160;&#160;Best Response of PR&#160;&#160;Best Response of SD&#160;&#160;Best Response of PD&#160;&#160;Ongoing&#160;&#160;Percent Change from Baseline&#160;&#160;800 mg q3w&#160;&#160;800 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;2400 mg
              q3w&#160;&#160;240 mg q3w&#160;&#160;240 mg q3w&#160;&#160;800 mg q3w&#160;&#160;Head and Neck&#160;&#160;Head and Neck&#160;&#160;Head and Neck&#160;&#160;Uveal Melanoma&#160;&#160;NSCLC&#160;&#160;Melanoma&#160;&#160;Melanoma&#160;&#160;Liver&#160;&#160;RCC&#160;&#160;RCC&#160;&#160;TNBC&#160;&#160;Squamous Cell Skin Carcinoma&#160;&#160;Part A2&#160;&#160;Yap T et al. SRK-181, a latent TGF&#946;1 inhibitor:
              safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors (Poster 780); Presented at SITC; Nov. 10-11, 2022. *Clinical cutoff date: August 29,
              2022.&#160;&#160;Response is assessed using RECIST v1.1 by PI; the scan is performed during screening, 6 weeks after first dose, every 9 weeks for the next 6 months of treatment, and every 12 weeks thereafter. SRK-181 is an investigational drug
              candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Part B (as of 8/29/22)&#160;&#160;14 patients
              enrolled&#160;&#160;One additional&#160;confirmed PR ongoing patient with anti-PD-1 resistant clear cell renal cell carcinoma &#160;&#160;All dose levels were generally well tolerated including recommended SRK-181 dose of 1500 mg q3w or 1000 mg q2w in combination
              with anti&#8209;PD-(L)1 for Part B &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide29.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Encouraging Early Clinical Data Consistent with Hypothesis &#160;&#160;29&#160;&#160;TGF&#946; pathway evaluation
              (PD)&#160;&#160;Target engagement (blood)&#160;&#160;TGF&#946;-1 signaling (tumor p-SMAD2 &amp; RNAseq)&#160;&#160;Immunophenotyping, including immune exclusion status&#160;&#160;Tumor immune contexture (e.g., tumor CD8+ T cells)&#160;&#160;Immune cell contexture (tumor &amp; blood
              MDSC&#8217;s)&#160;&#160;Immune response markers (e.g., IO gene signature) &#160;&#160;Therapeutically relevant dose&#160;&#160;Drug exposure needed for efficacy&#160;&#160;Objective response&#160;&#160;Anti-tumor response and survival benefits&#160;&#160;TGF&#946; pathway evaluation (PD)&#160;&#160;Target engagement
              (blood)&#160;&#160;TGF&#946;-1 signaling (tumor p-SMAD2 &amp; RNAseq)&#160;&#160;Immunophenotyping, including immune exclusion status&#160;&#160;Tumor immune contexture (e.g., tumor CD8+ T cells)&#160;&#160;Immune cell contexture (tumor &amp; blood MDSC&#8217;s)&#160;&#160;Immune response markers
              (e.g., IO gene signature)&#160;&#160;Therapeutically relevant dose&#160;&#160;Dosing regimens achieved target steady state levels&#160;&#160;Objective response&#160;&#160;Anti-tumor response observed (partial responses)&#160;&#160;Preclinical Data&#160;&#160;Phase 1 DRAGON proof-of-concept trial&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide30.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;30&#160;&#160;*(PD-1/PD-L1)&#160;&#160;First in class monoclonal antibody targeting latent and context-independent binding
              to TGF&#946;1&#160;&#160;Differentiated from other TGF&#946; inhibitors by its novel selectivity&#160;&#160;Offers potential to avoid toxicity and dose-limiting challenges of non-selective TGF&#946; inhibition approaches&#160;&#160;Differentiation&#160;&#160;Emerging evidence implicates TGF&#946;1 as
              driving resistance to checkpoint inhibitor therapies&#160;&#160;Potent and selective inhibitor of latent TGF&#946;1 activation in preclinical studies&#160;&#160;Strong safety and preclinical efficacy data&#160;&#160;Strong&#160;&#160;Scientific&#160;&#160;Rationale&#160;&#160;DRAGON Part A demonstrated
              ability to escalate to high doses of SRK-181 at levels exceeding the anticipated efficacious drug exposure level&#160;&#160;Advanced to DRAGON Part B: Evaluating SRK-181 in 5 parallel tumor-specific cohorts, with efficient path towards early POC for
              each&#160;&#160;Early efficacy signals have been observed&#160;&#160;Clear&#160;&#160;Clinical&#160;&#160;Pathway&#160;&#160;PD-(L)1* becoming a standard of care therapy in many tumor types; the market for synergistic combination product would be vast&#160;&#160;SRK-181 could potentially be used in
              many tumor types, potentially both in patients resistant to PD-(L)1 and in CPI na&#239;ve patients, as well as other therapeutic applications&#160;&#160;High Unmet&#160;&#160;Medical Need&#160;&#160;&amp; Large&#160;&#160;Commercial Opportunity&#160;&#160;SRK-181Summary&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide31.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Next Horizon: Fibrosis&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide32.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TGF&#946; is Established as Key Driver of Fibrosis Across Multiple Diseases &#160;&#160;32&#160;&#160;Nature Reviews , April 25,
              2016&#160;&#160;NATURE REVIEWS | NEPHROLOGY&#160;&#160;TGF-&#946;: the master regulator of fibrosis&#160;&#160;Xiao-ming Meng1, David J. Nikolic-Paterson2 and Hui Yao Lan3&#160;&#160;Nature Reviews. August 19, 2014&#160;&#160;NATURE REVIEWS | RHEUMATOLOGY&#160;&#160;Transforming growth factor &#946;&#8213;at the
              centre&#160;&#160;of systemic sclerosis&#160;&#160;Robert Lafyatis&#160;&#160;Int. J. Mol. Sci. August 27, 2018&#160;&#160;Targeting TGF-&#946; Signaling in Kidney Fibrosis&#160;&#160;Yoshitaka Isaka&#160;&#160;J. Am. Soc. Nephrol. December 3, 2017&#160;&#160;Targeting Anti-TGF-&#946; Therapy to Fibrotic Kidneys&#160;&#160;with a
              Dual Specificity Antibody Approach&#160;&#160;Steve McGaraughty,* Rachel A. Davis-Taber,&#8224; Chang Z. Zhu,* Todd B. Cole,*&#160;&#160;Arthur L. Nikkel,* Meha Chhaya,&#8224; Kelly J. Doyle,* Lauren M. Olson,* Gregory M. Preston,&#8224;&#160;&#160;Chrisine M. Grinnell,&#8224; Katherine M.
              Salte,* Anthony M. Giamis,* Yanping Luo,*&#160;&#160;Victor Sun,&#8224; Andrew D. Goodearl,&#8224; Murali Gopalakrishnan,* and Susan E. Lacy&#8224;&#160;&#160;J Pathol, July 25, 2021&#160;&#160;TGF-&#946; as a driver of fibrosis: physiological roles and therapeutic opportunities&#160;&#160;Erine H
              Budi1,&#160;Johanna R Schaub1,&#160;Martin Decaris1,&#160;Scott Turner1,&#160;Rik Derynck2&#160;&#160;J Receptors Sign Trans, Feb 13, 2020&#160;&#160;Inevitable role of TGF-&#946; in progression of nonalcoholic fatty liver disease&#160;&#160;Bhagyalakshmi Nair and Lekshmi R. Nath&#160;&#160;PNAS, February
              24, 1986&#160;&#160;Transforming growth factor type &#946;: Rapid induction of fibrosis and&#160;&#160;angiogenesis in vivo and stimulation of collagen formation in vitro&#160;&#160;ANITA B. ROBERTS* MICHAEL B. SPORN*, RICHARD K. ASSOIAN*, JOSEPH M. SMITH*, NANETTE S. ROCHE*,
              LALAGE M. WAKEFIELD*, URSULA I. HEINE*, LANCE A. LIOTTA*, VINCENT FALANGA&#8224;, JOHN H. KEHRL&#8225;, AND ANTHONY S. FAUCI&#8225;&#160;&#160;Proc Am Thorac Soc, July 3, 2006&#160;&#160;Transforming Growth Factor &#946;&#160;&#160;A Central Modulator of Pulmonary and Airway Inflammation and
              Fibrosis&#160;&#160;Dean Sheppard&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide33.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;GARP Presents TGF&#946; on Tregs&#160;&#160;LRRC33 Presents TGF&#946; on Macrophages&#160;&#160;LTBP1 &amp; 3 Present TGF&#946; in
              Connective Tissue&#160;&#160;Targeting Presenting Molecule/TGF&#946;-1 Complexes Provides Context Specificity &#160;&#160;Targeting Latent TGF&#946;-1 Complexes Creates Multiple &#8220;Handles&#8221; For Selectivity&#160;&#160;33&#160;&#160;Latent TGF-&#946;&#160;&#160;GARP&#160;&#160;Treg&#160;&#160;Integrin expressing
              cell&#160;&#160;avb8&#160;&#160;Integrin&#160;&#160;Latent TGF-&#946;&#160;&#160;LRRC33&#160;&#160;Macrophage&#160;&#160;Integrin expressing cell&#160;&#160;avb8&#160;&#160;Integrin&#160;&#160;Latent TGF-&#946; &#160;&#160;binding protein&#160;&#160; (LTBP)&#160;&#160;Extracellular matrix&#160;&#160;Fibrillin&#160;&#160;Latent TGF-&#946;&#160;&#160;Epithelial&#160;&#160;Cell&#160;&#160;avb6&#160;&#160;Integrin&#160;&#160;Latent TGF&#946;-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide34.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;LTBP-49247 Reduces TGF&#946;&#160;Signaling and Fibrosis in Preclinical Models of&#160;Kidney Fibrosis&#160;&#160;34&#160;&#160;LTBP-49247
              reduces a TGF&#946; PD biomarker in kidneys of&#160;Col4a3 KO mice (Alport Syndrome model)&#160;&#160;LTBP-49247 reduces fibrosis in&#160;kidneys of Alport model&#160;&#160;** p &lt; 0.01&#160;&#160;One way ANOVA vs. IgG&#160;&#160;HYP=hydroxyproline&#160;&#160;Efficacy also seen in rat model of kidney
              fibrosis &#160;&#160;No observed toxicity in mouse 13-week non-GLP repeat dose study&#160;&#160;Favorable PK in cynomolgus monkeys (t1/2 ~28 days) suggests LTBP-49247 is amenable to clinical subcutaneous dosing with promising developability profile&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide35.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Significant Opportunities to Address High Unmet Need Across Multiple Fibrotic Indications&#160;&#160;35&#160;&#160;Alport
              Syndrome (AS) &#160;&#160;Focal Segmental Glomerulosclerosis (FSGS) &#160;&#160;IgA Nephropathy (IgAN)&#160;&#160;Primary Sclerosing Cholangitis (PSC)&#160;&#160;Diffuse Cutaneous Systemic Sclerosis (dcSSc)&#160;&#160;Idiopathic Pulmonary Fibrosis (IPF)&#160;&#160;Collectively, significant commercial
              potential given large patient population with clear high unmet need given poor outcomes and lack of effective therapeutics&#160;&#160;Significant impact to delay or stop progression to end-stage disease and organ transplant &#160;&#160;Expansion opportunities
              via other indications given shared etiologies&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide36.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Next Horizon: Iron-Restricted Anemia&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide37.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;BMP6/RGMc Pathway is a Well Validated Regulator of Systemic Iron Homeostasis &#160;&#160;Fig: Muckenthaler, M.U.,
              Rivella, S., Hentze, M.W. and Galy, B. (2017) A Red Carpet for Iron Metaboism. Cell, 168(3): 344-361&#160;&#160;1: Kuns-Hashimoto R, et al. (2008) Selective binding of RGMc/hemojuvelin, a key protein in systemic iron metabolism, to BMP-2 and neogenin.
              Am J Physiol Cell Physiol 294(4):C994-C1003&#160;&#160;2: Constante M, et al.. (2007) Repression of repulsive guidance molecule C during inflammation is independent of Hfe and involves tumor necrosis factor-alpha. Am J Pathol 170(2):497-504&#160;&#160;3: Core
              A.B., et al. (2014) Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 5:104. &#160;&#160;4. Wang CY and Babitt JL. (2016) Hepcidin Regulation in the Anemia of Inflammation. Curr Opin Hematol 23(3):
              189-197.&#160;&#160;Elevation proinflammatory cytokines drives increased hepcidin expression and results in anemia due to functional iron deficiency4&#160;&#160;Anemia of Inflammation/ Chronic Disease&#160;&#160;Hepcidin&#160;&#160;Serum iron&#160;&#160;Untreated&#160;&#160;Hepcidin&#160;&#160;Serum iron&#160;&#160;Ab
              treated&#160;&#160;Human mutations in HJV/RGMc establish it as a central player in hepcidin regulation1&#160;&#160;Knockout phenotypes and tissue-specific expression pattern demonstrate that its predominant role is in iron homeostasis2&#160;&#160;Member of repulsive
              guidance molecule (RGM) family (RGMa, RGMb, RGMc/HJV) that act as BMP co-receptors to modulate BMP signaling3&#160;&#160;HJV/RGMc is a key player in the regulation of hepcidin expression&#160;&#160;37&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide38.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;HJV-35202: A High-Affinity Antibody Demonstrating Selective Inhibition of HJV/RGMc and Robust PK/PD in
              Cynos&#160;&#160;38&#160;&#160;Potent in vitro binding affinity (KD=3.9E-11)&#160;&#160;Highly specific to RGMc/HJV with well understood mechanism&#160;&#160;Sustained PD effect in single dose Cyno study&#160;&#160;Specific to RGMc over other RGM family members&#160;&#160;Nicholls S.B., et al. Poster:
              RGMc-selective antibodies modulate iron homeostasis in vivo, 12th International BMP Conference, Tokyo, October 2018&#160;&#160;Scholar Rock, Data on File&#160;&#160;High-affinity antibody&#160;&#160;Specific to RGMc, with mechanism of specificity
              understood&#160;&#160;Cross-reactive to human, mouse, rat and cyno&#160;&#160;Sustained PD observed in healthy rats and cynos, with clear PK/PD relationship&#160;&#160;Highly manufacturable framework with no sequence liabilities&#160;&#160;Formulatable into a subcutaneous format
              (150 mg/mL)&#160;&#160;HJV-35202 (mg/mL)&#160;&#160;Serum Iron and UIBC (mg/dL) &#160;&#160;PK: HJV-35202 (10mg/kg, IV)&#160;&#160;PD: UIBC: HJV-35202 (10mg/kg, IV)&#160;&#160;PDF: Serum Iron: HJV-35202 (10mg/kg, IV)&#160;&#160;Octet Response Units&#160;&#160;RGMa&#160;&#160;RGMb&#160;&#160;RGMc/HJV&#160;&#160;RGMa&#160;&#160;RGMb&#160;&#160;RGMc/HJV&#160;&#160;Key
              Attributes of HJV-35202:1,2&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide39.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Significant Opportunities to Target Iron-Restricted Anemias Across Multiple Indications&#160;&#160;39&#160;&#160;Chronic
              Kidney Disease (CKD)&#160;&#160;Anemia of Chronic Inflammation (AI)&#160;&#160;Myelofibrosis (MF)&#160;&#160;Targeting RGMc/HJV for anemia is well validated and relatively de-risked&#160;&#160;High levels of hepcidin, the main regulator of systemic iron metabolism, is associated
              with anemia across various diseases&#160;&#160;Safe and convenient RGMc inhibitor has promise of improving patient outcomes across multiple indications as stand alone or in combination with SoC &#160;&#160;Significant and clear unmet need given lack of approved
              treatments or severe limitations of current treatments&#160;&#160;Well defined patient population&#160;&#160;Collectively, sizeable commercial opportunity given relatively large population&#160;&#160;Potential for rapid with clear regulatory path&#160;&#160;Opportunity to build an
              anemia franchise with initial POC and indication expansion in the future&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide40.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Scholar Rock Summary &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide41.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;41&#160;&#160;Key Investment Highlights&#160;&#160;Revolutionary Platform&#160;&#160;Overcome the Challenges&#160;&#160;targeting the latent
              forms of growth factors&#160;&#160;Discover and Develop&#160;&#160;monoclonal antibodies with extraordinary selectivity&#160;&#160;Positioned For Success&#160;&#160;Upcoming Data Readouts&#160;&#160;for both clinical programs&#160;&#160;$205M financing in June 2022&#160;&#160;Year end cash balance of $315M,
              anticipated runway into 2025&#160;&#160;Robust Clinical Pipeline&#160;&#160;SRK-181 (Phase 1)&#160;&#160;Potential to shift current treatment landscape for cancer patients with CPI resistance&#160;&#160;Apitegromab (Phase 3)&#160;&#160;Potential first-in-class&#160;&#160;Significant market opportunity
              &#160;&#160;Program on track&#160;&#160;Clear path to approval&#160;&#160;Discovery-stage Pipeline&#160;&#160;Fibrosis and iron-restricted anemia&#160;&#160;Strategic optionality &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide42.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Appendix&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide43.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Plateau of HFMSE increases observed following initial treatment effect of risdiplam, although longer
              timeframes currently under investigation &#160;&#160;HFMSE=Hammersmith Functional Motor Scale-Expanded. &#160;&#160;Mercuri E, et al. Presented at: World Muscle Society Congress 2020, P. 257&#160;&#160;Oskoui M, et al. Presented at: 2021 Muscular Dystrophy Association
              Clinical &amp; Scientific Conference; March 15-18, 2021. Poster 80. &#160;&#160;* Overall population 2-25 years old.&#160;&#160;This third-party information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical
              trial results. &#160;&#160;Plateauing of HFMSE increases observed following initial treatment effects for nusinersen&#160;&#160;Motor Gains in Patients with Types 2 and 3 SMA on SMN Therapies Appear to Plateau After Initial
              Gains&#160;&#160;43&#160;&#160;Risdiplam2*&#160;&#160;Nusinersen1&#160;&#160;Mean (+SE) Change in HFMSE&#160;&#160;Total Score From Baseline&#160;&#160;Analysis Visit, days&#160;&#160;Initial Treatment&#160;&#160;CHERISH&#160;&#160;Chronic Maintenance Phase&#160;&#160;SHINE&#160;&#160;1&#160;&#160;92&#160;&#160;169&#160;&#160;253&#160;&#160;350&#160;&#160;450&#160;&#160;690&#160;&#160;930&#160;&#160;1170&#160;&#160;1410&#160;&#160;1650&#160;&#160;Mean Change
              From Baseline &#160;&#160;in HFMSE Total Score&#160;&#160;Visit, months&#160;&#160;0&#160;&#160;4&#160;&#160;8&#160;&#160;12&#160;&#160;18&#160;&#160;24&#160;&#160;Risdiplam&#160;&#160;Placebo&#160;&#160;&lt;1-point increase in HFMSE after ~ first year of treatment&#160;&#160;3.9&#160;&#160;Points&#160;&#160;4.6&#160;&#160;Points&#160;&#160;Unmet Need for Motor Function Gains&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide44.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;1. Mercuri E, et.al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J
              Med. 2018;378:625-635.&#160;&#160;2. Efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) Roche/PTC Therapeutics&#160;&#160;This third-party information is provided for background only and is not
              intended to convey or imply a comparison to the TOPAZ clinical trial results&#160;&#160;Nusinersen CHERISH Trial in Later-Onset SMA1&#160;&#160;In patients with later-onset SMA who were age &gt;5 at screening:&#160;&#160;Primary benefit of nusinersen: stabilization of
              motor function&#160;&#160;Majority of patients do not experience HFMSE increases&#160;&#160;Non-Ambulatory Type 2/3 SMA: Majority of Patients Started on SMN Therapy After Age 5 Do Not Experience Motor Function Increases&#160;&#160;44&#160;&#160;Risdiplam SUNFISH Trial in
              Later-Onset SMA2&#160;&#160;Low percentage of patients over the age of 5 achieved &#8805;3-point increase on MFM32 scale, even with risdiplam treatment&#160;&#160;HFMSE secondary endpoint showed a mean 0.58-point improvement over placebo (not statistically
              significant) &#160;&#160;Change &#160;From Baseline&#160;&#160;to 15 Months in HFMSE Score&#160;&#160;&#160;Age, year&#160;&#160;2&#160;&#160;4&#160;&#160;6&#160;&#160;8&#160;&#160;Nusinersen (N=66)&#160;&#160;Control (N=34)&#160;&#160;% of patients with &gt; 3 change in &#160;&#160;MFM32 total at Month 12&#160;&#160;Change in MFM32 total score&#160;&#160;2-5 Years&#160;&#160;6-11
              Years&#160;&#160;12-17 Years&#160;&#160;18-25 Years&#160;&#160;Risdiplam&#160;&#160;Placebo&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide45.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SAPPHIRE Phase 3 Design is Optimized by Insights from TOPAZ&#160;&#160;45&#160;&#160;Largest HFMSE gains observed in the
              non-ambulatory Type 2/3 SMA cohorts&#160;&#160;Exploratory age 2-12 analysis in non-ambulatory&#160;&#160;Type 2/3 showed transformative potential&#160;&#160;HFMSE gains evident by 12 months of treatment&#160;&#160;Dose response seen&#160;&#160;(greater effect observed with 20 mg/kg over 2
              mg/kg)&#160;&#160;Study population: Non-ambulatory Type 2/3 SMA&#160;&#160;Primary efficacy endpoint: HFMSE&#160;&#160;Age 2-12 main efficacy population&#160;&#160;12-month treatment duration&#160;&#160;20 mg/kg apitegromab dose&#160;&#160;Also evaluating 10 mg/kg arm (to explore potential that dose
              between 2 and 20 mg/kg may be comparable to 20 mg/kg)&#160;&#160;TOPAZ Learnings&#160;&#160;SAPPHIRE Design Elements&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide46.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Subject Disposition, Demographics and Baseline Characteristics1,2&#160;&#160;46&#160;&#160;AMBULATORY
              PATIENTS&#160;&#160;NON-AMBULATORY PATIENTS&#160;&#160;COHORT 1&#160;&#160;COHORT 2&#160;&#160;COHORT 3&#160;&#160;20 mg/kg&#160;&#160;monotherapy&#160;&#160;20 mg/kg + nusinersen&#160;&#160;20 mg/kg + nusinersen&#160;&#160;2 mg/kg +&#160;&#160;nusinersen&#160;&#160;20 mg/kg +&#160;&#160; nusinersen&#160;&#160;N (dosed)&#160;&#160;11&#160;&#160;12&#160;&#160;15&#160;&#160;10&#160;&#160;10&#160;&#160;Mean age at screening (min,
              max)&#160;&#160;12.1 (7, 19)&#160;&#160;13.1 (7, 21)&#160;&#160;11.7 (8, 19)&#160;&#160;4.1 (2, 6)&#160;&#160;3.8 (2, 6)&#160;&#160;Mean age at SMA diagnosis (min, max)&#160;&#160;5.9 (2, 15)&#160;&#160;4.5 (2, 15)&#160;&#160;3.1 (1, 16)&#160;&#160;1.2 (1, 2)&#160;&#160;1.2 (1, 3)&#160;&#160;Female (%)&#160;&#160;73%&#160;&#160;58%&#160;&#160;53%&#160;&#160;30%&#160;&#160;50%&#160;&#160;SMN2 Gene Copy* (#, %)&#160;&#160;2&#160;&#160;1
              (9%)&#160;&#160;0 (0%)&#160;&#160;1 (10%)&#160;&#160;1 (10%)&#160;&#160;3&#160;&#160;4 (36%)&#160;&#160;9 (75%)&#160;&#160;11 (73%)&#160;&#160;8 (80%)&#160;&#160;8 (80%)&#160;&#160;4&#160;&#160;4 (36%)&#160;&#160;1 (8%)&#160;&#160;2 (13%)&#160;&#160;1 (10%)&#160;&#160;0 (0%)&#160;&#160;# of maintenance doses of nusinersen&#160;&#160;at baseline (min, max)&#160;&#160;N/A&#160;&#160;5.6 (2, 8)&#160;&#160;5.1 (2, 9)&#160;&#160;5.5 (2, 9)&#160;&#160;5.4 (3,
              8)&#160;&#160;Discontinuation(s)&#160;&#160;0&#160;&#160;2&#8224;&#160;&#160;1&#8224;&#160;&#160;0&#160;&#160;0&#160;&#160;Scoliosis (#, %)&#160;&#160;7 (63.6)&#160;&#160;4 (33.3)&#160;&#160;11 (73.3)&#160;&#160;4 (40%)&#160;&#160;3 (30%)&#160;&#160;Contracture(s) (#, %)&#160;&#160;6 (54.5)&#160;&#160;7 (58.3)&#160;&#160;13 (86.7)&#160;&#160;8 (80%)&#160;&#160;4 (40%)&#160;&#160;Mean RHS score (min, max)&#160;&#160;47.6 (26, 63)&#160;&#160;51.3 (43, 62)&#160;&#160;Mean
              HFMSE score (min, max)&#160;&#160;22.7 (13, 39)&#160;&#160;26.1 (12, 44)&#160;&#160;23.5 (14, 42)&#160;&#160;*1 patient answered 3-4, 1 patient answered &gt;4 , both patients are in Cohort 1 treated with 20 mg/kg + nusinersen; data not available for all patients.&#160;&#160;&#160;&#8224;1 cohort 1
              patient discontinued study in 12M Treatment Period, 1 cohort 1 patient and 1 cohort 2 patient discontinued during 24M Extension Period A. All discontinuations were&#160;for reasons unrelated to study drug.&#160;&#160;&#160;HFMSE=Hammersmith Functional Motor
              Scale Expanded; RHS=Revised Hammersmith Scale.&#160;&#160;Crawford T et al.&#160;Presented at: 2022 Annual SMA Conference; June 16-19, 2022; Anaheim, CA. 2. Data on file; Scholar Rock. 2022.&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide47.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Non-Ambulatory Type 2 High Dose Cohort: Initiated nusinersen age &lt;51,2&#160;&#160;47&#160;&#160;Sizable increases in
              HFMSE observed in patients already treated with chronic maintenance nusinersen&#160;&#160;Improved: 88% (7/8)&#160;&#160;&#8805; 5-point increase: 63% (5/8)&#160;&#160;&gt; 10-point increase: 38% (3/8)&#160;&#160;Continuous and durableimprovements observed through12-months of
              treatment&#160;&#160;Apitegromab (20 mg/kg) + nusinersen&#160;&#160;n=8*&#160;&#160;Mean change from baseline in HFMSE&#160;&#160;(95% CI)&#160;&#160;+7.1&#160;&#160;&#160;(1.8, 12.5)&#160;&#160;# (%) patients achieving:&#160;&#160;&#8805; 1-pt increase in HFMSE&#160;&#160;7/8 (88%)&#160;&#160;&#8805; 3-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;&#8805; 5-pt increase in
              HFMSE&#160;&#160;5/8 (63%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=10&#160;&#160;Age&#160;&#160;3.8 (2, 6)&#160;&#160;HFMSE score&#160;&#160;23.5 (14, 42)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.4 (3, 8)&#160;&#160;*This was a primary intent-to-treat (ITT) analysis that, as prespecified, excluded
              2 patients who missed 3 doses due to COVID-19 related site access restrictions. An all-patients sensitivity analysis that included those 2 patients had similar results as this primary ITT analysis.&#160;&#160;&#160;Crawford T et al. TOPAZ topline results;
              Presented at&#160;CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021. 2. Data on file; Scholar Rock. 2022.&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy.
              Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide48.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Non-Ambulatory Type 2/3 Cohort: Initiated nusinersen age &#8805;51,2&#160;&#160;48&#160;&#160;Majority of patients improved in
              HFMSE (despite initiating background nusinersen age &#8805; 5)&#160;&#160;&#8805; 1-point increase: ~67%&#160;&#160;&#8805; 3-point increase: ~30%&#160;&#160;Durability of effect observed through 12-months of treatment&#160;&#160;*Intent-to-treat analysis excluded 1 patient (per prespecified
              approach) who missed 3 doses due to COVID-19 related site access restrictions; 1 patient who had inadvertently been enrolled who was receiving (and continued to receive) an acetylcholinesterase inhibitor was removed, which is not permitted
              per the trial protocol; 1.&#160;Crawford T et al. TOPAZ topline results; Presented at&#160;CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021. 2. Data on file. Scholar Rock, Inc.&#160;Apitegromab is an investigational drug
              candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Apitegromab (20 mg/kg)
              + nusinersen&#160;&#160;Per Protocol Population* &#160;&#160;(n=13)&#160;&#160;Intent-to-Treat Population&#160;&#160;(n=14)&#160;&#160;Mean change from baseline in HFMSE &#160;&#160;(95% CI)&#160;&#160;+1.2 &#160;&#160;(-0.5, 2.9)&#160;&#160;+0.6&#160;&#160; (-1.4, 2.7)&#160;&#160;# (%) patients achieving:&#160;&#160;&#8805; 1-pt increase in HFMSE&#160;&#160;9/13 (69%)&#160;&#160;9/14
              (64%)&#160;&#160;&#8805; 3-pt increase in HFMSE&#160;&#160;4/13 (31%)&#160;&#160;4/14 (29%)&#160;&#160;&#8805; 5-pt increase in HFMSE&#160;&#160;2/13 (15%)&#160;&#160;2/14 (14%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=15&#160;&#160;Age&#160;&#160;11.7 (8, 19)&#160;&#160;HFMSE score&#160;&#160;22.7 (13, 39)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.1
              (2, 9)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide49.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Topline 12-Month Data Showed Apitegromab&#8217;s Transformative Potential in Patients with Type 2/3
              SMA&#160;&#160;49&#160;&#160;Crawford T et al. TOPAZ topline results; Presented at CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021&#160;&#160;* Pooled cohorts of non-ambulatory patients treated with apitegromab 20 mg/kg and 2
              mg/kg&#160;&#160;**Non-ambulatory patients who initiated background nusinersen at a young age of &lt;5 years and treated with apitegromab 20 mg/kg dose. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal
              muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;HFMSE change from baseline&#160;&#160;Majority of non-ambulatory patients* experienced
              HFMSE increases from apitegromabduring chronic maintenance phase of SMN therapy&#160;&#160;Apitegromab led to HFMSE improvements in both non-ambulatory cohortsincluding patients started on nusinersen at age &#8805; 5&#160;&#160;Initiated background nusinersen &#160;&#160;Age
              &lt; 5**&#160;&#160;Age &#8805; 5&#160;&#160;Mean HFMSE Increase&#160;&#160;+7.1 points&#160;&#160;+0.6 points&#160;&#160;&#8805; 1-point Increase % (n/N)&#160;&#160;88% (7/8)&#160;&#160;64% (9/14)&#160;&#160;&#8805; 3-point Increase% (n/N)&#160;&#160;63% (5/8)&#160;&#160;29% (4/14)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide50.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;*Pooled cohorts of non-ambulatory patients treated with apitegromab 20 mg/kg and 2 mg/kg; excludes 4
              patients who each missed 3 doses of apitegromab due to COVID-19-related site access restrictions and were not included in the primary (intent-to-treat) analysis. &#160;&#160;Data on file. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an
              investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been
              established.&#160;&#160;HFMSE change from baseline&#160;&#160;Youngest &#160;&#160;(2 years)&#160;&#160;Oldest&#160;&#160; (19 years)&#160;&#160;Age of patient at baseline in TOPAZ&#160;&#160;HFMSE Improvements Observed Across Age Range of Non-Ambulatory Patients with Relatively Larger Gains from Earlier
              Treatment&#160;&#160;50&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide51.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;WHO Motor Development Milestone Achievements Further Support Apitegromab&#8217;s Potential to Improve Motor
              Function1&#160;&#160;&#160;51&#160;&#160;Non-ambulatory Type 2/3 Patients&#160;&#160;# of patients gaining &#8805; 1&#160;&#160;WHO motor milestone(s)&#160;&#160;Pooled&#160;&#160;7/35&#160;&#160;Initiated nusinersen age &lt; 5&#160;&#160;4/20&#160;&#160;Initiated nusinersen age &#8805; 5&#160;&#160;3/15&#160;&#160;WHO motor milestone analysis included all patients
              who completed the 12-month treatment period, including 4 patients who missed 3 doses of apitegromab due to COVID-19-related site access restrictions. Median baseline score for both non-ambulatory cohorts was 1.0.&#160;&#160;&#160;Pictures are not of
              patients with SMA and are not meant to be representative of patients with SMA. &#160;1.&#160;Crawford T et al. TOPAZ topline results; Presented at&#160;CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021&#160;&#160;1 patient (initiated
              nusinersen age &#8805;5) gained 2 new motor milestones&#160;&#160;1 patient (initiated nusinersen age &lt;5, 20 mg/kg) gained 3 new motor milestones&#160;&#160;Sitting&#160;&#160;without support&#160;&#160;Standing with&#160;&#160;assistance&#160;&#160;Walking with&#160;&#160;assistance&#160;&#160;Walking&#160;&#160;alone&#160;&#160;Following&#160;&#160;12
              months of apitegromab treatment...&#160;&#160;Hands &amp; knees crawling&#160;&#160;Standing alone&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide52.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Significance of Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module
              (RULM)&#160;&#160;52&#160;&#160;HFMSE&#160;&#160;Assesses the physical abilities of patients with Types 2/3 SMA&#160;&#160;ABLE TO:&#160;&#160;Touch Head Above Ear Level&#160;&#160;whilst maintaining stable trunk and head&#160;&#160;Roll From Supine to Prone&#160;&#160;over the right side without pulling/ pushing on
              hands&#160;&#160;33 Items&#160;&#160;Graded on scale 0 to 2&#160;&#160;0 = unable&#160;&#160;1 = performed with modification or adaptation&#160;&#160;2 = without modification or adaptation &#160;&#160;Item scores are summed to give a total score &#160;&#160;The higher the total score, the greater the patient&#8217;s
              motor function&#160;&#160;Maximum score: 66&#160;&#160;Examples of items:&#160;&#160;One hand to head in sitting&#160;&#160;Rolls supine to prone&#160;&#160;Lying to sitting&#160;&#160;Four&#8211;point kneeling&#160;&#160;Supported standing&#160;&#160;Stepping&#160;&#160;Ascends 4 stairs with railing&#160;&#160;RULM&#160;&#160;Evaluates Motor Performance
              in Upper Limbs&#160;&#160;ABLE TO:&#160;&#160;Bring Token&#160;&#160;to Cup&#160;&#160;placed vertically at shoulder height&#160;&#160;Bring Weight at Eye Level using two hands&#160;&#160;19 Items&#160;&#160;Graded on scale 0 to 2(Except for 1 activity with a binary score)&#160;&#160;0 = unable&#160;&#160;1 = able with
              modification&#160;&#160;2 = able with no difficulty&#160;&#160;Evaluated upper limb tasks correspond to ability to perform everyday activities&#160;&#160;Maximum score: 37&#160;&#160;Examples of items:&#160;&#160;Putting a coin into a cup&#160;&#160;Elevating a cup to mouth&#160;&#160;Picking up a
              coin&#160;&#160;Bringing hand to shoulder&#160;&#160;Lifting up weighted objects&#160;&#160;Opening a zip lock bag &#160;&#160;Drawing a line on paper&#160;&#160;O&#8217;Hagen et al. 2007; Glanzman et al. 2011; Hammersmith Functional Motor Scale Expanded for SMA (HFMSE) Manual, 2019&#160;&#160;Mazzone et
              al. 2017; Pierzchlewicz et al. 2021; Revised Upper Limb Module for SMA Manual, 2014 &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide53.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TOPAZ Extension Period: 24-Month Patient Disposition &#160;&#160;53&#160;&#160;&#160;&#160;&#160;Cohort 1&#160;&#160; Ambulatory &#160;&#160;Non&#8211;Ambulatory
              &#160;&#160;Cohort 2&#160;&#160;Cohort 3&#160;&#160; Total &#160;&#160;# Non-Ambulatory Patients (2-21)&#160;&#160;&#160;&#160;&#160;15&#160;&#160;20&#160;&#160;35&#160;&#160;# Non-Ambulatory Patients (2-12)&#160;&#160;&#160;&#160;&#160;9&#160;&#160;20&#160;&#160;29&#160;&#160;Dropped Out (0-12 M)&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;Dropped Out (12-24 M)&#160;&#160;1&#160;&#160;1&#160;&#160;&#160;0&#160;&#160;1&#160;&#160;Not Having Valid HFMSE testing at Month
              24&#160;&#160;Not applicable&#160;&#160;5*&#160;&#160;1**&#160;&#160;6&#160;&#160;Not Having RULM at Month 24&#160;&#160;Not applicable&#160;&#160;2***&#160;&#160;1****&#160;&#160;3&#160;&#160;# of patients who received scoliosis surgery &#160;&#160;1&#160;&#160;2*****&#160;&#160;1&#160;&#160;3&#160;&#160;* Includes 1 patient who withdrew from study; 1 patient off schedule due to scheduled
              surgery; 1 patient who had hip pain; 1 patient with femur fracture; and 1 patient who refused to be in supine position.&#160;&#160;** Patient with bilateral lower extremity cast&#160;&#160;*** Includes 1 patient withdrew from study, and 1 patient off schedule
              due to planned surgery.&#160;&#160;**** Patient was too young for RULM at baseline and RULM was not conducted at following visit.&#160;&#160;***** Patients did not have valid HFMSE test at 24 months.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide54.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-015 20 mg/kg (N=10)&#160;&#160;SRK-015 2 mg/kg (N=10)&#160;&#160;Strong Evidence of Dose Response Observed Over 24
              Months Further Supported by Data from Low Dose to High Dose Switch in Non-Ambulatory Patients&#160;&#160;54&#160;&#160;20 mg/kg throughout&#160;&#160;Switched from &#160;&#160;2 mg/kg to 20 mg/kg&#160;&#160;Dose-switching period&#160;&#160;Crawford T et al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND
              SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TYPE 2 AND TYPE 3 SMA) Podium Presentation Presented at CureSMA; June 2022&#160;&#160;This analysis excludes from the Observed Case Analysis the HFMSE data attained
              post-scoliosis surgery during TOPAZ. Error bars represent SEM. &#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any
              other health authority, and its safety and efficacy have not been established.&#160;&#160;Mean Change from Baseline in HFSME Scores Over Time (Cohort 3)&#160;&#160;Excludes data after scoliosis surgery&#160;&#160;Change from Baseline of HFSE Score&#160;&#160;Time
              (Weeks)&#160;&#160;10&#160;&#160;8&#160;&#160;4&#160;&#160;2&#160;&#160; 0&#160;&#160;6&#160;&#160;0&#160;&#160;16&#160;&#160;36&#160;&#160;52&#160;&#160;68&#160;&#160;84&#160;&#160;104&#160;&#160;8&#160;&#160;24&#160;&#160;40&#160;&#160;1/9 patients switched from 2 to 20 mg/kg&#160;&#160;9/10 patients switched from 2 to 20 mg/kg&#160;&#160;All patients switched from 2 to 20 mg/kg&#160;&#160;Year 2&#160;&#160;Year 1&#160;&#160;Sample Size at Each
              Visit&#160;&#160;Cohort 3 SRK 2 mg/kg&#160;&#160;10&#160;&#160;10&#160;&#160;10&#160;&#160;7&#160;&#160;8&#160;&#160;9&#160;&#160;9&#160;&#160;9&#160;&#160;10&#160;&#160;10&#160;&#160;Cohort 3 SRK 20 mg/kg&#160;&#160;10&#160;&#160;10&#160;&#160;10&#160;&#160;8&#160;&#160;8&#160;&#160;10&#160;&#160;8&#160;&#160;10&#160;&#160;10&#160;&#160;8&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide55.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Reported Impact of Scoliosis Surgery on Motor Abilities in SMA&#160;&#160;55&#160;&#160;Dunaway Young et al.
              2020&#160;&#160;Scoliosis Surgery&#160;&#160;HFMSE Total Score&#160;&#160;3-month post-surgery assessment&#160;&#160;14/17&#160;&#160;Lost &gt;3 points on the HFMSE (mean change = - 12.1, SD = 8.9) &#160;&#160;Functionally meaningful change &#160;&#160;13/17&#160;&#160;Minimal HFMSE changes within &#177; 2 points (mean change
              = - 0.7)&#160;&#160;No change or stability&#160;&#160;0/17&#160;&#160;Improvement &gt; 2 points post-surgery&#160;&#160;Post-Surgery HFMSE scores Type 2/3 SMApeer-reviewed study &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide56.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Sizable, Sustained Increases in HFMSE Observed At 24 Months of ApitegromabPooled Non-Ambulatory
              Patients &#160;&#160;56&#160;&#160;Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients treated with the lower dose 2 mg/kg and does not exclude any patients who missed apitegromab doses due to
              COVID-19 site access restrictions. Error bars represent standard error of the mean (SEM). Values in parentheticals represent 95% confidence interval. Data on File. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an investigational drug
              candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Mean Change from
              Baseline in HFMSE (95% CI) &#160;&#160;Age 2-21 Years&#160;&#160;Age 2-12 Years&#160;&#160;n=&#160;&#160;35&#160;&#160;29&#160;&#160;32&#160;&#160;29&#160;&#160;n=&#160;&#160;29&#160;&#160;23&#160;&#160;26&#160;&#160;24&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide57.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Strong Evidence of Dose Response Observed Over 24 MonthsFurther Supported by Data from Low Dose to High
              Dose Switch in Non-Ambulatory Patients &#160;&#160;57&#160;&#160;Most patients in Cohort 3 who switched from &#160;&#160;2 mg/kg to 20 mg/kg continued to show HFMSE improvement&#160;&#160;Study Day&#160;&#160;Patient with scoliosis surgery &#160;&#160;Apitegromab is an investigational drug candidate
              being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;.&#160;&#160;Change from Baseline of HFSE
              Score&#160;&#160;20 mg/kg Throughout&#160;&#160;2 mg/kg &#8594; 20 mg/kg&#160;&#160;Study day is relative to the date of the first dose of 20 mg/kg&#160;&#160;Change from Baseline of HFSE Score&#160;&#160;Benefit maintained through 24-month timepoint &#160;&#160;Rapid Increase&#160;&#160;Continued improvement after
              switch &#160;&#160;Gradual increases of HFMSE at 2 mg/kg&#160;&#160;Switch to 20 mg/kg&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide58.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Continued Increase in RULM Observed at 24 Months of Apitegromab Pooled Non-Ambulatory Patients
              &#160;&#160;58&#160;&#160;Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients treated with the lower dose 2 mg/kg and does not exclude any patients who missed apitegromab doses due to COVID-19
              site access restrictions. Data on File. Scholar Rock, Inc. Cambridge, MA. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US
              FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Age 2-21 Years&#160;&#160;Age 2-12 Years&#160;&#160;n=&#160;&#160;34&#160;&#160;28&#160;&#160;31&#160;&#160;33&#160;&#160;n=&#160;&#160;28&#160;&#160;22&#160;&#160;25&#160;&#160;28&#160;&#160;Mean Change from Baseline in RULM (95% CI) &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide59.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Cohort 3: Mean RULM Score Change Over TimeRULM Trended Up in Low Dose Arm Patients After Switch to High
              Dose&#160;&#160;59&#160;&#160;Observed Case Analysis is based upon data available for a given timepoint, and this analysis population includes patients treated with the lower dose 2 mg/kg and does not exclude any patients who missed apitegromab doses due to
              COVID-19 site access restrictions. Error bars represent standard error of the mean (SEM). Error bars represent SEM.&#160;&#160;Crawford T et al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR
              ATROPHY (TYPE 2 AND TYPE 3 SMA) Podium&#160;Presentation Presented at&#160;CureSMA; June 2022. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use
              by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Cohort 3 SRK 2 mg/kg&#160;&#160;10&#160;&#160;10&#160;&#160;10&#160;&#160;7&#160;&#160;8&#160;&#160;9&#160;&#160;9&#160;&#160;9&#160;&#160;10&#160;&#160;10&#160;&#160;Cohort 3 SRK 20 mg/kg&#160;&#160;10&#160;&#160;10&#160;&#160;10&#160;&#160;8&#160;&#160;8&#160;&#160;10&#160;&#160;8&#160;&#160;10&#160;&#160;10&#160;&#160;8&#160;&#160;Sample Size at Each
              Visit&#160;&#160;Change from Baseline of RULM Score&#160;&#160;Time (Weeks)&#160;&#160;0&#160;&#160;16&#160;&#160;36&#160;&#160;52&#160;&#160;68&#160;&#160;84&#160;&#160;104&#160;&#160;4&#160;&#160;3&#160;&#160;1&#160;&#160;0&#160;&#160; -1&#160;&#160;2&#160;&#160;8&#160;&#160;24&#160;&#160;40&#160;&#160;Mean Change from Baseline in RULM Scores Over Time (Cohort 3)&#160;&#160;Excludes data after scoliosis surgery&#160;&#160;SRK-015 20 mg/kg
              (N=10)&#160;&#160;SRK-015 2 mg/kg (N=10)&#160;&#160;1 of 9 patients in Cohort 3 switched from 2 mg/kg to 20 mg/kg&#160;&#160;9 of 10 patients in Cohort 3 switched from to 2 mg/kg to 20 mg/kg&#160;&#160;All patients in Cohort 3 switched from 2 mg/kg to 20 mg/kg&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide60.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Correlation of HFMSE to RULM Increased Over 24 MonthsPooled Non-Ambulatory Patients &#160;&#160;60&#160;&#160;Crawford T et
              al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND SAFETY OF APITEGROMAB IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TYPE 2 AND TYPE 3 SMA) Podium Presentation Presented at CureSMA; June 2022.&#160;&#160;This analysis is based on the Observed Case
              Analysis population. The 12-month graph displays all patients who had a valid measurement at visit 15 (Day 364) and the 24-month graph displays all patients who had a valid measurement at extension visit 14 (Day 728).; Apitegromab is an
              investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;-
              Basil Darras, MD Associate Neurologist-in-Chief, Boston Children&#8217;s Hospital; &#160;&#160;Professor of Neurology, Harvard Medical School; TOPAZ trial Investigator&#160;&#160;&#8220;The observation that the majority of patients in this analysis experienced gains in both
              the HFMSE and RULM over 24 months further supports the therapeutic potential of apitegromab.&#8221;&#160;&#160;r = 0.28&#160;&#160;p = 0.1216&#160;&#160;n= 31&#160;&#160;RULM and HFMSE Change from Baseline at 12 Months&#160;&#160;Observed Cases&#160;&#160;RULM Change from Baseline at V15/Day 364&#160;&#160;HFMSE
              Change from Baseline at V15/Day 364&#160;&#160;95% Confidence Limits&#160;&#160;Regression&#160;&#160;r = 0.58&#160;&#160;p = 0.0011&#160;&#160;n=28 &#160;&#160;RULM and HFMSE Change from Baseline at 24 Months&#160;&#160;Observed Cases&#160;&#160;RULM Change from Baseline at EXT14/Day 728&#160;&#160;HFMSE Change from Baseline at
              EXT14/Day 728&#160;&#160;95% Confidence Limits&#160;&#160;Regression&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide61.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;PEDI-CAT:&#160;&#160;Measure of activities of daily living&#160;&#160;PROMIS (Fatigue):&#160;&#160;Measure of Patient Fatigue &#160;&#160;ESBBT
              (Fatigability):&#160;&#160;Measure of how fast a patient fatigues&#160;&#160;1&#160;&#160;2&#160;&#160;3&#160;&#160;PRO measurement tool4&#160;&#160;Muscle endurance measurement tool6&#160;&#160;4-point scale (1=unable to 4=easy) assessment of various activities, higher scores reflect improved
              abilities1,2&#160;&#160;PEDI-CAT has been validated in SMA, but alone cannot identify small changes in function across all types of SMA3&#160;&#160;Measures mild subjective feelings of tiredness to debilitating and sustained feelings of exhaustion, with lower
              scores reflecting less fatigue4,5&#160;&#160;Has been utilized to assess fatigue and fatigability in the Cure SMA database, but has not been fully validated in SMA5&#160;&#160;Part of a series of endurance shuttle tests that include: nine-hole peg test, box and
              block test, and walk test (ESNHPT, ESBBT, and ESWT)6&#160;&#160;Patients are asked to move blocks individually from one box to another in one minute, with higher numbers of blocks suggesting higher muscle endurance6&#160;&#160;The endurance shuttle tests have
              been validated for use in patients with SMA7&#160;&#160;Measures pediatric abilities through 3 functional domains, daily activities, mobility, and social cognitive1&#160;&#160;Activities of Daily Living and Fatigue: Assessed by Three Measures&#160;&#160;61&#160;&#160;ADL,
              activities of daily living; ESBBT, endurance shuttle box and block test; ESNHPT, endurance shuttle nine-hole peg test; ESWT, endurance shuttle walk test; PEDI-CAT, pediatric evaluation of disability inventory computer adaptive test; PROMIS,
              patient-reported outcomes measurement information system; PRO(s), patient-reported outcome(s); SMA, spinal muscular atrophy. 1. Cre Care. PEDI-CAT. Accessed April 26, 2022. https://www.pedicat.com/. 2. Data on file; Scholar Rock. 2022. 3.
              Pasternak A, et al. Muscle Nerve. 2016;54(6):1097-1107. 4. NIH. PROMIS. Accessed April 26, 2022. https://commonfund.nih.gov/promis/index. 5. Belter L, et al. Orphanet Journal of Rare Diseases. 2020;15:217. 6. Cure SMA. Best Practices for
              Physical Therapists and Clinical Evaluators in Spinal Muscular Atrophy (SMA). 2021. Available at: https://www.curesma.org/wp-content/uploads/2021/09/Clinical-Evaluators-Best-Practices-13-August-2021.pdf. 7. Bartels B, et al. Orphanet Journal
              of Rare Diseases. 2020;15:75. &#160;&#160;PEDI-CAT, PROMIS, and ESBBT &#160;&#160;Used to assess:&#160;&#160;ADL&#160;&#160;Fatigue&#160;&#160;Muscle Endurance&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide62.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Non-Ambulatory Patients Showed Continuous Improvements in ADL and Fatigue Measures Over 24 Months of
              Apitegromab Treatment1,2&#160;&#160;62&#160;&#160;Tertiary Endpoints: Improvements in ADL and Fatigue&#160;&#160;Apitegromab treatment in non-ambulatory type 2 resulted in patients improving in patient-reported outcomes related to self-sufficiency and
              fatigue&#160;&#160;Non-Ambulatory Type 2&#160;&#160;&#8805;2 years&#160;&#160;nusinersen initiated before 5 years of age(95% CI)&#160;&#160;12&#160;&#160;MONTH&#160;&#160;24&#160;&#160;MONTH&#160;&#160;ADL, activities of daily living; PEDI-CAT, the Pediatric Evaluation of Disability Inventory computer adaptive test; PROMIS,
              Patient-Reported Outcome Measurement Information System. 1.&#160;Crawford T et al. P.102. Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study Neuromuscular Disorders.2022;&#160;32 (SUPPLEMENT 1): S86-S87; 2.
              Crawford T et al. P.102. Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study; Poster Presented and Poster Highlights Podium Presentation presented WMS October 2022. Apitegromab is an investigational
              drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been
              established.&#160;&#160;Improvement&#160;&#160;PARENT&#160;&#160;FATIGUEMean change in PROMIS parent&#160;&#160;DECREASE: &#8211;5.5 &#160;&#160;(&#8211;10.1, &#8211;0.9)&#160;&#160;(n=4)&#160;&#160;DECREASE: &#8211;5.0 &#160;&#160;(&#8211;8.9, &#8211;1.1)&#160;&#160;(n=10)&#160;&#160;MOBILITY&#160;&#160;Mean change in &#160;&#160;PEDI-CAT mobility&#160;&#160;INCREASE: 0.4 &#160;&#160;(&#8211;2.4, 3.2)&#160;&#160;(n=11)&#160;&#160;INCREASE:
              2.6 &#160;&#160;(0.4, 4.7)&#160;&#160;(n=14)&#160;&#160;ADL&#160;&#160;Mean change in &#160;&#160;PEDI-CAT activities&#160;&#160;INCREASE: 1.9 &#160;&#160;(&#8211;0.3, 4.1)&#160;&#160;(n=11)&#160;&#160;INCREASE: 3.0 &#160;&#160;(1.8, 4.1)&#160;&#160;(n=14)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide63.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Apitegromab treatment in non-ambulatory types 2 and 3 resulted in patients improving in
              patient-reported outcomes related to self-sufficiency and fatigue&#160;&#160;Non-Ambulatory Patients Showed Stabilization or Improvements in ADL and Fatigue Measures over 24 Months of Apitegromab Treatment1,2&#160;&#160;63&#160;&#160;Tertiary Endpoints: Improvements in
              ADL and Fatigue&#160;&#160;Improvement&#160;&#160;Non-AmbulatoryType 2/3&#160;&#160;5-21 years&#160;&#160;nusinersen initiated after 5 years of age(95% CI)&#160;&#160;12&#160;&#160;MONTH&#160;&#160;24&#160;&#160;MONTH&#160;&#160;ADULT&#160;&#160;FATIGUEMean change in PROMIS adult&#160;&#160;DECREASE: &#8211;3.5 &#160;&#160;(&#8211;35.3, 28.3)&#160;&#160;(n=2)&#160;&#160;DECREASE: &#8211;3.5
              &#160;&#160;(&#8211;9.9, 2.9)&#160;&#160;(n=2)&#160;&#160;PARENT&#160;&#160;FATIGUEMean change in PROMIS parent&#160;&#160;DECREASE: -0.6 &#160;&#160;(&#8211;5.9, 4.7)&#160;&#160;(n=10)&#160;&#160;DECREASE: -1.3 &#160;&#160;(-6.7, 4.0)&#160;&#160;(n=9)&#160;&#160;ADL&#160;&#160;Mean change in &#160;&#160;PEDI-CAT activities&#160;&#160;INCREASE: 0.9 &#160;&#160;(&#8211;1.4, 3.2)&#160;&#160;(n=12)&#160;&#160;INCREASE: 0.7
              &#160;&#160;(-1.8, 3.2)&#160;&#160;(n=8)&#160;&#160;ADL, activities of daily living; PEDI-CAT, the Pediatric Evaluation of Disability Inventory computer adaptive test; PROMIS, Patient-Reported Outcome Measurement Information System. 1.&#160;Crawford T et al.
              P.102.&#160;Apitegromab&#160;in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study Neuromuscular Disorders.2022;&#160;32&#160;(SUPPLEMENT 1): S86-S87; 2. Crawford T et al. P.102.&#160;Apitegromab&#160;in SMA: An analysis of multiple efficacy
              endpoints in the TOPAZ extension study; Poster Presented and&#160;Poster Highlights Podium Presentation presented WMS October 2022. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy.
              Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide64.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Non-Ambulatory Patients Continued to Improve in Fatigability and Endurance Measures, Which May be
              Complementary to Upper Limb Function Improvements over 24 Months1&#160;&#160;64&#160;&#160;The ESBBT is the first validated and sensitive fatigability test for proximal arm function in SMA and may be complementary to outcome measures that focus on arm motor
              function such as the RULM, by adding the dimension of endurance2&#160;&#160;Trends of improvements with ESBBT correlate with RULM over 24 months &#160;&#160;ESBBT, endurance shuttle box and block test; SMA, spinal muscular atrophy; SMN, survival motor neuron;
              QoL, quality of life. 1.Darras BT, et al. Apitegromab in SMA (TOPAZ trial): Efficacy, Safety, and PK/PD Assessments From 24- Month Data; Podium Presentation presented at SMAEU; October 2022 . 2. Mazzone ES, et al. RULM for SMA: development of
              a new module. Muscle Nerve. 2017;55(6):869&#8211;74. Baseline is defined as the last measurement prior to the first dose of study drug. Subject visits after an intercurrent event of 3 consecutive missed doses during the Extension A period, or after
              taking nusinersen for SMN up-regulator therapy if in Cohort1, are excluded from the Efficacy Eligible Set. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been
              approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Apitegromab treatment in non-ambulatory types 2 and 3 (cohort 2) resulted in patients improving in QoL assessments
              related to self-sufficiency and endurance&#160;&#160;Tertiary Endpoints: Improvements in Fatigability&#160;&#160;Improvement&#160;&#160;Non-AmbulatoryType 2/3&#160;&#160;5-21 years&#160;&#160;nusinersen initiated before5 years of age(95% CI)&#160;&#160;12&#160;&#160;MONTH&#160;&#160;24&#160;&#160;MONTH&#160;&#160;ENDURANCE&#160;&#160;Mean change in
              &#160;&#160;ESBBT activities&#160;&#160;INCREASE: 281&#160;&#160;&#160;(&#8211;22.7, 584.2)1&#160;&#160;(n=8)&#160;&#160;INCREASE: 147.9 &#160;&#160;(0.6, 295.2)1&#160;&#160;(n=8)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide65.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Therapeutic Potential of Apitegromab Observed in the Ambulatory Type 3 SMA Cohort at 24
              Months1-4&#160;&#160;65&#160;&#160;Ambulatory Patients&#160;&#160;(Revised Hammersmith Scale; RHS)&#160;&#160;24-Month Analysis&#160;&#160;COHORT 1&#160;&#160;20 mg/kg pooled1&#160;&#160;(n=21)&#160;&#160;20 mg/kg&#160;&#160;Monotherapy4 (n=11)&#160;&#160;20 mg/kg + nusinersen2,3 (n=10)&#160;&#160;Mean change from baseline, (95% CI)&#160;&#160;-1.8 (-4.7,
              1.1)&#160;&#160;-2.8 (-8.4, 2.8)&#160;&#160;-0.7 (-3.1, 1.7)&#160;&#160;Patients achieving &#8805; 1-pt increase, n (%)&#160;&#160;9/21 (42.9%)&#160;&#160;5/11 (45.5%)&#160;&#160;4/10 (40%)&#160;&#160;Patients achieving &#8805; 3-pt increase, n (%)&#160;&#160;5/21 (23.8%)&#160;&#160;3/11 (27.3%)&#160;&#160;2/10 (20%)&#160;&#160;Observed Case Analysis includes
              all patients who had a valid measurement at E14 (Day 728). Inclusive of data from 3 patients in apitegromab monotherapy who lost ability to ambulate. 1.&#160;Crawford T et al. TOPAZ EXTENSION: 24-MONTH EFFICACY AND SAFETY OF APITEGROMAB IN
              PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY (TYPE 2 AND TYPE 3 SMA) Podium Presentation Presented at CureSMA; June 2022. 2.&#160;Crawford T et al. P.102. Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension
              study Neuromuscular Disorders.2022;&#160;32 (SUPPLEMENT 1): S86-S87. 3. Crawford T et al. P.102. Apitegromab in SMA: An analysis of multiple efficacy endpoints in the TOPAZ extension study; Poster Presented and Poster Highlights Podium
              Presentation presented WMS October 2022. 4. Data on File,&#160;Scholar Rock Inc. 2022.&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by
              the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide66.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Fourteen patients experienced a serious TEAE, all assessed by the respective trial investigator as
              unrelated to apitegromab:&#160;&#160;One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to adenoidal hypertrophy and tonsillar hypertrophy to perform scheduled adenotonsillectomy (Grade 2). Events resolved without sequelae.&#160;&#160;Two
              patients treated with 20 mg/kg dose (both Cohort 1) presented with gait inability considered a significant disability (both Grade 3). Events remain ongoing.&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 1) was hospitalized with post lumbar
              puncture syndrome (Grade 2). Event resolved without sequelae.&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 1) was hospitalized due to viral upper respiratory tract infection (Grade 2). Event resolved without sequelae.&#160;&#160;Five patients
              treated with 20 mg/kg dose (one from Cohort 1, three from Cohort 2, and one from Cohort 3) were hospitalized for spinal fusion surgery/ scoliosis/ scoliosis surgery (all Grade 3). All events resolved without sequelae.&#160;&#160;One patient treated
              with 20 mg/kg dose (Cohort 1) was hospitalized due to bilateral developmental hip dysplasia and left hip dislocation (both Grade 3). Events resolved without sequelae.&#160;&#160;One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to
              hip dislocation (Grade 3). Event resolved with sequelae (anxiety and post-operative pain).&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 3) was hospitalized due to respiratory syncytial virus infection (Grade 2). Events resolved without
              sequelae.&#160;&#160;One patient treated with 2 mg/kg dose (Cohort 3) was hospitalized due to vomiting and pneumonia (Grade 3). Events resolved without sequelae.&#160;&#160;Overall Safety and Tolerability Profile Over 24 Months of Treatment: Serious
              TEAEs&#160;&#160;66&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy
              have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide67.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Four patients presented with non-serious Grade 3 events, all assessed by the respective trial
              investigator as unrelated to apitegromab:&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 1) presented with post lumbar puncture syndrome. Event resolved without sequelae.&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 2) presented with
              worsening of scoliosis. Event resolved (with surgery, reported as serious, above) without sequelae.&#160;&#160;One patient treated with 20 mg/kg dose (Cohort 2) presented with osteopenia. Events remains ongoing.&#160;&#160;One patient treated with 2 mg/kg
              (Cohort 3) presented with two instances of hypoglycemia and one instance of metabolic acidosis. All events resolved without sequelae.&#160;&#160;One patient (Cohort 1) discontinued from the trial due to Grade 2 muscle fatigue that started prior to
              initiation of dosing with study drug; assessed by the trial investigator as unrelated to apitegromab.&#160;&#160;Overall Safety and Tolerability Profile Over 24 Months of Treatment: Non-Serious Grade 3 Events&#160;&#160;67&#160;&#160;Apitegromab is an investigational drug
              candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide68.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181: Transformative Potential as the Backbone For Next Era of Cancer Therapy&#160;&#160;68&#160;&#160;CPI
              Combination&#160;&#160;(solid tumors)&#160;&#160;Other Combinations (solid tumors)&#160;&#160;&amp; Hematologic&#160;&#160;Other immunotherapies&#160;&#160;Chemotherapy &#160;&#160;XRT&#160;&#160;Otherapplications&#160;&#160;Myelofibrosis&#160;&#160;Liquid tumors&#160;&#160;1st line immunotherapy&#160;&#160;First in class&#160;monoclonal antibody
              targeting&#160;latent&#160;and context-independent&#160;binding to TGFB-1&#160;&#160;CURRENT FOCUS&#160;&#160;Primary and AcquiredCPI resistance&#160;&#160;Investigation in primary (pre-existing) CPI resistance offers path to early clinical POC for SRK-181&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide69.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Regulatory T cell&#160;&#160;Tumor Associated &#160;&#160;Macrophage&#160;&#160;Cancer Associated Fibroblasts (Stromal cells)&#160;&#160;Tumor
              cells&#160;&#160;SRK-181 &#160;&#160;Targets latent TGF&#946;-1 &#160;&#160;Inhibits activation of latent TGF&#946;-1 across ALL compartments&#160;&#160;Turns it off at the source&#160;&#160;Context-Independent: SRK-181 Inhibits Latent TGF&#946;-1 Across All Compartments of the Tumor
              Microenvironment&#160;&#160;69&#160;&#160;Latent TGF&#946;-1&#160;&#160;Key driver of tumor resistance to CPIs &#160;&#160;Present in multiple compartments of the tumor microenvironment&#160;&#160;TGF&#946; Latent growth factor&#160;&#160;TGF&#946; source presentation&#160;&#160;LRRC33&#160;&#160;GARP&#160;&#160;LTBPs&#160;&#160;LTBPs&#160;&#160;LRRC33:
              leucine-rich-repeat-containing protein family member 33 | LTBPs: latent transforming growth factor &#946; binding proteins | GARP: glycoprotein A repetitions predominant&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide70.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181 Therapeutic Hypothesis: Potential Advantages of Latent TGF&#946;-1
              Inhibitor&#160;&#160;70&#160;&#160;SRK-181*&#160;&#160;Bifunctional TGF&#946;/CPI &#160;&#160;ALK5 Inhibitor&#160;&#160;Nonselective TGF&#946; antibody&#160;&#160;Selectivity for TGF&#946;-1: potential for wider therapeutic window and improved safety&#160;&#160;Ability to combine with any anti-PD-(L)1&#160;&#160; &#160;&#160; &#160;&#160;Ability to
              optimize dosing of each component of combination therapy&#160;&#160;Activity spatially distinct from anti-PD-(L)1 in tissue&#160;&#160; &#160;&#160;Inhibits all sources of TGF&#946;-1 contributing to CPI resistance (Context independent)&#160;&#160;Target latent form (Blocks TGF&#946;-1
              activation)&#160;&#160;*SRK-181 is an investigational product candidate currently being evaluated in DRAGON phase 1 clinical trial. The efficacy and safety of SRK-181 have not been established. &#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide71.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;TGF&#946;-1 Blockade with SRK-181-mIgG1 Rendered Preclinical Tumor Models Susceptible to Anti-PD1
              Therapy&#160;&#160;71&#160;&#160;Days after treatment initiation&#160;&#160;Tumor volume (mm3)&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(3 mg/kg QW)&#160;&#160;4/14&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(10 mg/kg QW)&#160;&#160;8/14&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci
              Transl Med. 2020 Mar 25;12(536):eaay8456. https://scholarrock.com/platform/publications/.&#160;&#160;*SRK-181-mIgG1 is the murine version of SRK-181; responder defined as tumor size &lt;25% endpoint volume at study end.&#160;&#160;Bladder Cancer&#160;&#160;Breast Cancer
              (TGF&#946;-1/3 co-expressing)&#160;&#160;0/13&#160;&#160;Anti-PD1 (10 mg/kg BIW)&#160;&#160;0/10&#160;&#160;SRK-181-mIgG1* (10 mg/kg QW)&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(10 mg/kg QW)&#160;&#160;5/10&#160;&#160;Responders 0/9&#160;&#160;Control&#160;&#160;0/9&#160;&#160;Anti-PD1 (10 mg/kg BIW)&#160;&#160;SRK-181-mIgG1* (10 mg/kg QW)&#160;&#160;Responders
              0/12&#160;&#160;MBT-2 and EMT6 Models &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide72.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;SRK-181-mIgG1 Combination Treatment Led to Melanoma Tumor Regression and Survival Benefit
              &#160;&#160;72&#160;&#160;*P&lt;0.01. &#160;&#160;&#8224;P&lt;0.05 Log-rank (Mantel-Cox test) vs anti-PD1.&#160;&#160;*&#160;&#160;*&#160;&#160;&#8224;&#160;&#160;Days after treatment initiation&#160;&#160;Tumor Regression&#160;&#160;Survival Benefit&#160;&#160;Anti-PD1 + SRK-181-mlgG1 (30 mg/Kg/wk)&#160;&#160;Anti-PD1 + SRK-181-mlgG1 (3 mg/Kg/wk)&#160;&#160;Anti-PD1 +
              SRK-181-mlgG1 (10 mg/Kg/wk)&#160;&#160;Anti-PD1 (10 mg/Kg/2xwk)&#160;&#160;SRK-181-mlgG1 (30 mg/Kg/wk)&#160;&#160;Control&#160;&#160;Melanoma (Cloudman S91) model&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med. 2020 Mar
              25;12(536):eaay8456. https://scholarrock.com/platform/publications.&#160;&#160;Days after treatment initiation&#160;&#160;Monotherapy&#160;&#160;3/12&#160;&#160;Anti-PD1&#160;&#160;(10 mg/kg BIW)&#160;&#160;Tumor volume (mm3)&#160;&#160;SRK-181-mIgG1&#160;&#160;(30 mg/kg QW)&#160;&#160;Responders 0/12&#160;&#160;Combination Therapy&#160;&#160;Led to
              tumor regression and survival benefit&#160;&#160;Anti-PD1/SRK-181-mIgG1 (30 mg/kg QW)&#160;&#160;8/11&#160;&#160;Days after treatment initiation&#160;&#160;Anti-PD1/SRK-181-mIgG1 (10 mg/kg QW)&#160;&#160;Tumor volume (mm3)&#160;&#160;4/9&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide73.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Selectivity of SRK-181 Offers Potential to Overcome Toxicity and Dose-limiting Challenges of
              Non-selective TGF&#946; Pathway Approaches &#160;&#160;73&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med 2020 Mar 25;12(536): eaay8456. &#160;&#160;*Source: Anderton MJ, et al. Induction of heart valve lesions by
              small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39: 916-924.; and Stauber AJ, et al. Nonclinical safety evaluation of a transforming growth factor &#946; Receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J Clin Pract. 2014:
              4:3.&#160;&#160;Microscopic Observations in Heart&#160;&#160;Valvulopathy&#160;&#160;Atrium&#8212;Mixed cell infiltrate&#160;&#160;Myocardium&#8212;Degeneration/necrosis&#160;&#160;Myocardium&#8212;Hemorrhage&#160;&#160;Myocardium&#8212;Mixed cell infiltrate, base&#160;&#160;Coronary artery&#8212;Necrosis with
              inflammation&#160;&#160;Cardiomyocyte&#8212;Necrosis/inflammatory cell infiltrate&#160;&#160;CONTROL&#160;&#160;Vehicle&#160;&#160;iv, qwk x 4&#160;&#160;LY2109761&#160;&#160;300 mg/kg&#160;&#160;po, qd x 8&#160;&#160;PanTGF&#946;Ab&#160;&#160;30 mg/kg&#160;&#160;Iv, 1 dose&#160;&#160;10 mg/kg&#160;&#160;iv, qwk x 4&#160;&#160;30 mg/kg&#160;&#160;iv, qwk x 4&#160;&#160;100 mg/kg&#160;&#160;iv, qwk x
              4&#160;&#160;SRK-181&#160;&#160;Selective TGF&#946;-1 Toxicity: Minimal&#160;&#160;Non-selective TGF&#946;&#160;&#160;Toxicity: Minimal, slight and moderate&#160;&#160;Unremarkable&#160;&#160;Minimal&#160;&#160;Slight&#160;&#160;Moderate&#160;&#160;Toxicology:&#160;&#160;Repeat Dose Pilot Toxicology Study&#160;&#160;Adult female Sprague Dawley rats&#160;&#160;Cardiac
              findings were exhibited&#160;&#160;in animals dosed with pan-TGF&#946; antibody or LY2109761 (inhibitor of ALK5, common TGF&#946; receptor kinase) as expected based on published data&#8224;&#160;&#160;NO CARDIOTOXICITIES (valvulopathy)were noted with SRK-181 &#160;&#160;NOAEL for
              SRK-181: 100 mg/kg QW(highest dose evaluated)&#160;&#160;4-week GLP toxicology studies&#160;&#160;RATS&#160;&#160;NOAEL for SRK-181: 200 mg/kg QW (highest dose evaluated)&#160;&#160;NON-HUMAN PRIMATES&#160;&#160;NOAEL for SRK-181: 300 mg/kg(highest dose evaluated)&#160;&#160;Not test article related&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide74.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Bladder urothelial carcinoma&#160;&#160;Had &amp; neck squamous carcinoma&#160;&#160;Kidney clear cell carcinoma&#160;&#160;Kidney
              papillary cell carcinoma&#160;&#160;Liver hepatocellular carcinoma&#160;&#160;Lung adenocarcinoma&#160;&#160;Skin cutaneous melanoma&#160;&#160;Stomach adenocarcinoma&#160;&#160;Acute myeloid leukemia&#160;&#160;Adrenocortical cancer&#160;&#160;Brain lower grade glioma&#160;&#160;Breast invasive carcinoma&#160;&#160;Cervical &amp;
              endocervical cancer&#160;&#160;Cholangiocarcinoma&#160;&#160;Colon adenocarcinoma&#160;&#160;Diffuse large B-cell carcinoma&#160;&#160;Esophageal carcinoma&#160;&#160;Glioblastoma multiforme&#160;&#160;Kidney chromophobe&#160;&#160;Lung squamous cell carcinoma&#160;&#160;Mesothelioma&#160;&#160;Ovarian serous
              cystadenocarcinoma&#160;&#160;Pancreatic adenocarcinoma&#160;&#160;Pheochromocytoma &amp; paraganglioma&#160;&#160;Prostate adenocarcinoma&#160;&#160;Emerging Evidence Implicates TGF&#946;-1 as Driving Primary Resistance to Checkpoint Inhibitors&#160;&#160;74&#160;&#160;Human Tumor Analyses Reveal TGF&#946;-1
              as Most Likely Driver of TGF&#946; Signaling Pathway in Cancers&#160;&#160;&#8224;Priti H, et al. Top 10 challenges in cancer immunotherapy. Immunity. 2020 Jan 14:52(1):17-35. https://doi.org/10.1016/j.immuni.2019.12.011.&#160;&#160;*Source: National Cancer Institute -
              Cancer Genome Atlas Program.&#160;&#160;NSCLC&#160;&#160;TMB&#160;&#160;Low&#160;&#160;High&#160;&#160;Substantial % of Solid Tumors Exhibit Immune Exclusion&#160;&#160;Immune Excluded&#160;&#160;Immune Phenotype&#160;&#160;Inflamed&#160;&#160;Immune Desert&#160;&#160;Tumor Type&#160;&#160;Melanoma&#160;&#160;RCC&#160;&#160;UBC&#160;&#160;TNBC&#160;&#160;Gastric&#160;&#160;CRC
              MSS&#160;&#160;Pancreatic&#160;&#160;SCLC&#160;&#160;HR+BC&#160;&#160;Prostate&#160;&#160;Immune Excluded&#160;&#160;Inflamed&#160;&#160;Immune Desert&#160;&#160;Cancer Genome Atlas RNAseq Analysis of &gt;10,000 Samples Spanning 33 Tumor Types*&#160;&#160;TGFB1&#160;&#160;TGFB2&#160;&#160;TGFB3&#160;&#160;Scale&#160;&#160;% of patient samples (+)&#160;&#160;for TGF-&#946;
              isoform&#160;&#160;100&#160;&#160;80&#160;&#160;60&#160;&#160;40&#160;&#160;20&#160;&#160;0&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide75.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Biomarker Strategies Employed in DRAGON Trial&#160;&#160;75&#160;&#160;Multiple tissue-based and circulating biomarker
              analyses to be evaluated in DRAGON study&#160;&#160;Higher resolution histochemical characterization of tumor immune contexture (e.g. CD8+)&#160;&#160;Classification of inflamed, excluded or immune desert tumors and tumor nests&#160;&#160;Ability of SRK-181 to overcome
              tumor immune exclusion&#160;&#160;Analysis of immune response markers (e.g. PD-L1)&#160;&#160;Changes to intra-tumoral and/or circulating immune cell contexture (MDSC)&#160;&#160;Show evidence of the SRK-181 target engagement&#160;&#160;e.g. circulating TGF&#946;-1 levels&#160;&#160;TGF&#946; pathway
              modulation:&#160;&#160;e.g. Histochemical analysis of pSMAD&#160;&#160;e.g. RNA-based TGF&#946; gene signatures and pathway analyses&#160;&#160;Paired biopsies from the head and neck cohort allow for a potential to accelerate the development path&#160;&#160;Immunophenotyping&#160;&#160;Assessment
              of immune landscape&#160;&#160;TGF&#946;-1 pathway evaluation&#160;&#160;Assessment of signaling pathway&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide76.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Clear Evidence of Target EngagementPharmacodynamic Biomarker Results for Part A: Circulatory
              TGF&#946;-1&#160;&#160;76&#160;&#160;Yap T et al. SRK-181, a latent TGF&#946;1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors (Poster 780); Presented at SITC;
              Nov. 10-11, 2022. Circulatory TGF&#946;-1 and PF4 levels were quantitated by using validated ELISA kits from R&amp;D System.12 Because platelet activation during sample processing can lead to elevated TGF&#946;-1 levels, samples with elevated PF4, a
              platelet activation biomarker, were excluded from the analysis based on a preliminary cutoff value.&#160;&#160;Pre-infusion.&#160;&#160;SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been
              approved by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Binding to latent TGF&#946;-1 delays maturity state allowing TGF&#946;-1 to accumulate in system&#160;&#160;Combination treatment with pembrolizumab did
              not appear to impact circulatory TGF&#946;-1 levels&#160;&#160;C1D2&#160;&#160;C1D8&#160;&#160;C1D15&#160;&#160;C2D1*&#160;&#160;C3D1*&#160;&#160;C3D2&#160;&#160;C3D8&#160;&#160;C3D15&#160;&#160;C4D1*&#160;&#160;C5D1*&#160;&#160;Baseline&#160;&#160;Circulatory TGF&#946;-1&#160;&#160;(Fold-Change from Baseline)&#160;&#160;2&#160;&#160;3&#160;&#160;4&#160;&#160;6&#160;&#160;5&#160;&#160;Median Circulatory TGF&#946;-1 Increased Post-treatment
              with SRK-181 (Q3W, All Patients)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" id="slide">
        <div style="position: relative; left: 0px; top: 0px;" id="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/4df1da3c9eee8e701a6be66e4633432f-a53178569ex99_1slide77.jpg"></div>
        </div>
        <div style="text-align: center;" id="slideText">
          <div style="text-align: left;" id="slideTextFrame"><font style="color: white; display: inline; font-family: Times New Roman; font-size: 1pt;">&#160;Preclinical Data Provide Scientific Rationale to Evaluate Peripheral Samples for Evidence of SRK-181
              Activity&#160;&#160;77&#160;&#160;MBT-2 bladder tumor model IgG, anti-PD-1 and SRK-181-mIgG1 dosed d1, d7&#160;&#160;Analysis on day 10&#160;&#160;Circulating MDSC Levels Correlate&#160;&#160;with Tumor Volume&#160;&#160;Both tumoral and circulatory MDSC are being evaluated in the DRAGON
              study&#160;&#160;Immunophenotyping&#160;&#160;Assessment of immune landscape&#160;&#160;Measurement of MDSCs in circulation may provide indirect evidence of drug action on the tumor&#160;&#160;Myeloid-derived suppressor cells (MDSCs) have immune suppressive functions&#160;&#160;SRK-181 plus
              anti-PD1 combination drive MDSC levels down significantly in the tumor microenvironment&#160;&#160;Reductions in circulating MDSC levels correlate with reduced tumor volume following SRK-181 and anti-PD1 treatment in MBT-2 tumor
              model&#160;&#160;Anti-PD-1+&#160;&#160;SRK-181&#160;&#160; 1 mpk&#160;&#160; 3 mpk&#160;&#160; 10 mpk&#160;&#160;IgG Ctrl&#160;&#160;SRK-181&#160;&#160;Anti-PD-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" id="spaceAfterSlideText">&#160;</div>
    </div>
  </div>
</div>
</html>
<div><a name="a53178569ex99_2.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
  </head>
<div bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zc0942a796bc9484ca9728598dd918463">

        <tr>
          <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.2</font><br>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: left;">
      <div class="bw-release">
        <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Scholar Rock Provides Corporate Update and Highlights Priorities for 2023</b> </h1>
        <div class="bw-release-subhead">
          <p style="text-align: center; list-style-position: inside;"><b> - <i>Pivotal Phase 3 SAPPHIRE trial enrollment completion expected in 2023</i> </b></p>
          <p style="text-align: center; list-style-position: inside;"><b> - <i>Phase 1 DRAGON trial of SRK-181 continues to advance with presented data that showed early indications of efficacy; ongoing clinical data updates planned in 2023</i> </b></p>
          <p style="text-align: center; list-style-position: inside;"><b> - <i>Anticipated cash runway into 2025</i> </b></p>
        </div>
        <div class="bw-release-body">
          <div class="bw-release-table-js bw-release-story">
            <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--January 9, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
              provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023. </p>
            <p> &#8220;In 2022, Scholar Rock made significant progress in advancing its clinical programs, notably with the 24-month extension data from the Phase 2 TOPAZ trial, which reinforces our conviction behind apitegromab and the Phase 3 SAPPHIRE trial,
              and with early data readouts from the Phase 1 DRAGON trial. The company also strengthened its financials in June 2022 with a substantial equity raise. We are excited by the potential coming from our highly differentiated platform targeting
              growth factors like TGF&#946;, as we advance our spinal muscular atrophy and oncology programs to address critical unmet needs for patients,&#8221; said Dr. Jay Backstrom, M.D., M.P.H., President &amp; CEO of Scholar Rock. &#8220;In 2023, we see continued
              momentum for our growing pipeline, including completing enrollment of our pivotal SAPPHIRE trial, disclosing 36-month extension data from the Phase 2 TOPAZ trial and clinical and biomarker updates from the SRK-181 Phase 1 DRAGON trial, and
              advancing two preclinical assets towards IND-enabling studies in fibrosis and iron-restricted anemia.&#8221; </p>
            <p> <b>2023 Priorities:</b> </p>
            <p> <b><u>Apitegromab</u></b> is a selective inhibitor of myostatin activation being developed as the potential first muscle-targeted therapy for the treatment of spinal muscular atrophy (SMA). </p>
            <ul style="list-style-type: disc;">
              <li> <b>Complete enrollment of Phase 3 SAPPHIRE clinical trial in 2023</b>. SAPPHIRE is a randomized, double-blind, placebo-controlled clinical trial evaluating apitegromab for patients with nonambulatory Types 2 and 3 SMA on either
                nusinersen or risdiplam. The last patient is expected to be enrolled in SAPPHIRE in 2023, with the top-line data readout expected in 2024. If successful, the company expects to initiate a commercial product launch in 2025. </li>
              <li> <b>Progress TOPAZ long-term extension to 36-month data readout.</b> The company expects to report 36-month extension data in the first half of 2023. As of December 31, 2022, approximately 90 percent of patients (51/57) remained enrolled
                in the trial&#8217;s long-term extension period. </li>
            </ul>

            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> &#160; </p>
            <p> <b><u>SRK-181</u></b> is an investigational selective inhibitor of latent TGF&#946;-1 activation and is being developed with the aim of overcoming resistance to checkpoint therapy in patients with advanced cancer. </p>
            <ul style="list-style-type: disc;">
              <li> <b>Advance Progress in DRAGON Phase 1 trial. </b>Scholar Rock is expecting to provide biomarker and clinical updates from the DRAGON Phase 1 trial in 2023. </li>
            </ul>
            <p> <b><u>Preclinical fibrosis and iron-restricted anemia assets</u></b> </p>
            <ul style="list-style-type: disc;">
              <li> <b>Advance the fibrosis program towards IND-enabling studies. </b>Scholar Rock plans to advance a highly potent, anti-latent TGF&#946;-1 antibody that selectively inhibits TGF&#946;1 activation within the extracellular matrix by targeting latent
                TGF&#946;-1 associated with latent TGF&#946;-binding proteins (LTBPs), thus enabling specific inhibition of TGF&#946;-1 in fibrotic tissue. </li>
            </ul>
            <ul style="list-style-type: disc;">
              <li> <b>Advance the iron-restricted anemia program towards IND-enabling studies.</b> Scholar Rock plans to advance a highly selective, RGMc/HJV antibody that targets the signaling of BMP6, a key regulator of iron availability in the body.
                Utilizing Scholar Rock&#8217;s unique structural biology insights into BMP6 and its co-receptors and leveraging its novel antibody discovery and optimization platform, the company generated an anti-RGMc antibody that can modulate iron release and
                has the potential to address anemia. </li>
            </ul>
            <p> <b>2022 Highlights:</b> </p>
            <ul style="list-style-type: disc;">
              <li> TOPAZ 24-month extension trial data showed sizeable and sustained gains in Hammersmith Functional Motor Scale Expanded (HFMSE), increased Revised Upper Limb Module (RULM), and positive trends in quality-of-life data for nonambulatory
                patients with Types 2 and 3 SMA receiving an SMN-targeted therapy. </li>
              <li> Completed equity financing of $205 million in June. As of December 31, 2022, Scholar Rock had cash, cash equivalents, and marketable securities of approximately $315 million, which is expected to fund the company&#8217;s operations into 2025.
              </li>
              <li> Phase 1 DRAGON trial data presented at the Society for Immunotherapy of Cancer's Annual Meeting in November showed that SRK-181 continued to be generally well tolerated with early indications of efficacy (as of the data cut-off date of
                August 29, 2022). </li>
              <li> Presented new data on LTBP showing reduction of TGF&#946;-1 signaling and fibrosis in relevant in vivo preclinical models. The findings were presented at the 2022 FASEB Science Research Conference in July and the American College of
                Toxicology Annual Meeting in November. </li>
              <li> Announced Jay Backstrom, M.D., M.P.H. was appointed President &amp; CEO in October, bringing an exceptional range of research and development, regulatory, and leadership experience spanning several decades in the biopharmaceutical
                industry. </li>
              <li> Announced Jing L. Marantz, M.D., Ph.D., M.B.A., was appointed Chief Medical Officer in November. Dr. Marantz is an accomplished biopharmaceutical executive with over 20 years of industry experience spanning multiple specialties,
                including neurology, hematology/oncology, and rare diseases. </li>
            </ul>
            <p> &#8220;With our strong balance sheet and two well established clinical programs, both of which we expect to generate data in 2023, Scholar Rock is uniquely positioned to bring differentiated therapies to patients suffering from serious diseases
              in which protein growth factors play a fundamental role,&#8221; said Ted Myles, Chief Operating Officer and Chief Financial Officer. </p>

            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> <b>About Scholar Rock</b> </p>
            <p> Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar
              Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&#8217;s approach to
              targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the
              cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its
              focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
              (https://www.linkedin.com/company/scholar-rock/). </p>
            <p> <b>Availability of Other Information About Scholar Rock</b> </p>
            <p> Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and
              Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material
              information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in
              any filing under the Securities Act of 1933, as amended. </p>
            <p> Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc. </p>

            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> <b>Forward-Looking Statements</b> </p>
            <p> This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and
              prospects, including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development
              timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform.<i> </i>The
              use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such
              forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and
              adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial of
              apitegromab, or Part A of the Phase 1 clinical trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including, without limitation,
              the Phase 3 clinical trial of apitegromab in SMA or Part B of the Phase 1 clinical trial of SRK-181, Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the
              expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products
              for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any
              clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts
              of current macroeconomic and geopolitical events, including changing conditions from the COVID-19 pandemic, hostilities in Ukraine, increasing rates of inflation and rising interest rates, on business operations and expectations, as well as
              those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, as well as discussions of potential risks, uncertainties, and other important
              factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any
              subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. </p>
          </div>
          <div class="bw-release-contact">
            <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
            <p> <b>Scholar Rock:</b> </p>
            <p> <b>I</b><b>nvestors </b><br>
              Rushmie Nofsinger <br>
              Scholar Rock <br>
              rnofsinger@scholarrock.com <br>
              ir@scholarrock.com<br>
              857-259-5573 </p>
            <p> <b>Media </b><br>
              Ariane Lovell <br>
              Finn Partners <br>
              ariane.lovell@finnpartners.com <br>
              media@scholarrock.com<br>
              917-565-2204 </p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9206\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
